{"entity":"amgen","name":"Amgen","kind":null,"summary":"Amgen's timeline holds 525 claims from 2006 to 2026: 515 money & deals, 10 other. 9 are undated. The latest took effect on October 29, 2026.","counts":{"total":525,"by_kind":{"people":0,"money":515,"products":0,"models":0,"other":10}},"events":[{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen headquarters: Thousand Oaks\", undated. Claim clm_213F34219223, https://asof.is/claim/clm_213F34219223, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_213F34219223","accessed":"2026-11-08"},"kind":"other","predicate":"headquarters","value":"Thousand Oaks","status":"valid","assertable":true,"id":"clm_213F34219223","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen ticker: AMGN\", undated. Claim clm_3FB6D299561D, https://asof.is/claim/clm_3FB6D299561D, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_3FB6D299561D","accessed":"2026-11-08"},"kind":"other","predicate":"ticker","value":"AMGN","status":"valid","assertable":true,"id":"clm_3FB6D299561D","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen listed on: Nasdaq\", undated. Claim clm_4091015E92FD, https://asof.is/claim/clm_4091015E92FD, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_4091015E92FD","accessed":"2026-11-08"},"kind":"other","predicate":"listed_on","value":"Nasdaq","status":"valid","assertable":true,"id":"clm_4091015E92FD","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen state of incorporation: DE\", undated. Claim clm_56FF368E6750, https://asof.is/claim/clm_56FF368E6750, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_56FF368E6750","accessed":"2026-11-08"},"kind":"other","predicate":"state_of_incorporation","value":"DE","status":"valid","assertable":true,"id":"clm_56FF368E6750","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen registrant name: AMGEN INC\", undated. Claim clm_7924DEE14027, https://asof.is/claim/clm_7924DEE14027, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_7924DEE14027","accessed":"2026-11-08"},"kind":"other","predicate":"registrant_name","value":"AMGEN INC","status":"valid","assertable":true,"id":"clm_7924DEE14027","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen fiscal year end: 12-31\", undated. Claim clm_932BE2EE8880, https://asof.is/claim/clm_932BE2EE8880, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_932BE2EE8880","accessed":"2026-11-08"},"kind":"other","predicate":"fiscal_year_end","value":"12-31","status":"valid","assertable":true,"id":"clm_932BE2EE8880","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen sic industry: Biological Products, (No Diagnostic Substances) (2836)\", undated. Claim clm_EDF8DD683D0B, https://asof.is/claim/clm_EDF8DD683D0B, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_EDF8DD683D0B","accessed":"2026-11-08"},"kind":"other","predicate":"sic_industry","value":"Biological Products, (No Diagnostic Substances) (2836)","status":"valid","assertable":true,"id":"clm_EDF8DD683D0B","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cik: 0000318154\", undated. Claim clm_F44BD9859244, https://asof.is/claim/clm_F44BD9859244, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154.","url":"https://asof.is/claim/clm_F44BD9859244","accessed":"2026-11-08"},"kind":"other","predicate":"cik","value":"0000318154","status":"valid","assertable":true,"id":"clm_F44BD9859244","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen website: http://www.amgen.com/\", undated. Claim clm_DDCF286895FD, https://asof.is/claim/clm_DDCF286895FD, accessed 2026-11-08. Source: https://www.wikidata.org/wiki/Q470517.","url":"https://asof.is/claim/clm_DDCF286895FD","accessed":"2026-11-08"},"kind":"other","predicate":"website","value":"http://www.amgen.com/","status":"unverified","assertable":false,"why_not":"low_confidence","id":"clm_DDCF286895FD","evidence":{"by":"own-site","on":"2026-11-08","quote":"Amgen | A Worldwide Pioneer in Biotechnology.","url":"https://www.amgen.com/"}},{"date":"2006-12-31","until":"2007-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 1,283,000,000 United States dollar\", as of 2006-12-31 (until 2007-12-31). Claim clm_462973430FCC, https://asof.is/claim/clm_462973430FCC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_462973430FCC","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"1,283,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_462973430FCC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-03-01"}},{"date":"2006-12-31","until":"2007-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 19,841,000,000 United States dollar\", as of 2006-12-31 (until 2007-12-31). Claim clm_624B06744974, https://asof.is/claim/clm_624B06744974, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_624B06744974","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"19,841,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_624B06744974","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2009, filed 2010-03-01"}},{"date":"2007-12-31","until":"2008-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 14,771,000,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_51956A4A09F8, https://asof.is/claim/clm_51956A4A09F8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_51956A4A09F8","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"14,771,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_51956A4A09F8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2009, filed 2010-03-01"}},{"date":"2007-12-31","until":"2008-06-30","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 2,024,000,000 United States dollar\", as of 2007-12-31 (until 2008-06-30). Claim clm_58CEE3D787CB, https://asof.is/claim/clm_58CEE3D787CB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_58CEE3D787CB","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,024,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_58CEE3D787CB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-03-01"}},{"date":"2007-12-31","until":"2008-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 3,980,000,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_812C4678103A, https://asof.is/claim/clm_812C4678103A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_812C4678103A","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"3,980,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_812C4678103A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2009, filed 2010-03-01"}},{"date":"2007-12-31","until":"2008-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 18,512,000,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_8B4D216D886A, https://asof.is/claim/clm_8B4D216D886A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_8B4D216D886A","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"18,512,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8B4D216D886A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2009, filed 2010-03-01"}},{"date":"2007-12-31","until":"2008-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 3,078,000,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_BBC1534096ED, https://asof.is/claim/clm_BBC1534096ED, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_BBC1534096ED","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"3,078,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BBC1534096ED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2009, filed 2010-03-01"}},{"date":"2008-06-30","until":"2008-09-30","published":"2009-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 3,764,000,000 United States dollar\", as of 2008-06-30 (until 2008-09-30). Claim clm_17341E32AFF6, https://asof.is/claim/clm_17341E32AFF6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509169378/0001193125-09-169378-index.htm.","url":"https://asof.is/claim/clm_17341E32AFF6","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"3,764,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_17341E32AFF6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2009, filed 2009-08-10"}},{"date":"2008-06-30","until":"2008-09-30","published":"2009-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 906,000,000 United States dollar\", as of 2008-06-30 (until 2008-09-30). Claim clm_8016AE1D57BE, https://asof.is/claim/clm_8016AE1D57BE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509169378/0001193125-09-169378-index.htm.","url":"https://asof.is/claim/clm_8016AE1D57BE","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"906,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8016AE1D57BE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2009, filed 2009-08-10"}},{"date":"2008-06-30","until":"2008-09-30","published":"2009-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,179,000,000 United States dollar\", as of 2008-06-30 (until 2008-09-30). Claim clm_C4A7A3DD6E59, https://asof.is/claim/clm_C4A7A3DD6E59, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509169378/0001193125-09-169378-index.htm.","url":"https://asof.is/claim/clm_C4A7A3DD6E59","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,179,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C4A7A3DD6E59","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2009, filed 2009-08-10"}},{"date":"2008-06-30","until":"2008-09-30","published":"2009-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,392,000,000 United States dollar\", as of 2008-06-30 (until 2008-09-30). Claim clm_FA4F80522690, https://asof.is/claim/clm_FA4F80522690, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509169378/0001193125-09-169378-index.htm.","url":"https://asof.is/claim/clm_FA4F80522690","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,392,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FA4F80522690","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2009, filed 2009-08-10"}},{"date":"2008-09-30","until":"2009-03-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,121,000,000 United States dollar\", as of 2008-09-30 (until 2009-03-31). Claim clm_83CFCB7D01DA, https://asof.is/claim/clm_83CFCB7D01DA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509227739/0001193125-09-227739-index.htm.","url":"https://asof.is/claim/clm_83CFCB7D01DA","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,121,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_83CFCB7D01DA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2008-09-30","until":"2009-03-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,483,000,000 United States dollar\", as of 2008-09-30 (until 2009-03-31). Claim clm_A00D04DA0A77, https://asof.is/claim/clm_A00D04DA0A77, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509227739/0001193125-09-227739-index.htm.","url":"https://asof.is/claim/clm_A00D04DA0A77","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,483,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A00D04DA0A77","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2008-09-30","until":"2008-12-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 2,522,000,000 United States dollar\", as of 2008-09-30 (until 2008-12-31). Claim clm_B0CE0DC6AD30, https://asof.is/claim/clm_B0CE0DC6AD30, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509227739/0001193125-09-227739-index.htm.","url":"https://asof.is/claim/clm_B0CE0DC6AD30","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,522,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B0CE0DC6AD30","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2008-09-30","until":"2009-03-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 3,875,000,000 United States dollar\", as of 2008-09-30 (until 2009-03-31). Claim clm_D6A6F66C922D, https://asof.is/claim/clm_D6A6F66C922D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509227739/0001193125-09-227739-index.htm.","url":"https://asof.is/claim/clm_D6A6F66C922D","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"3,875,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D6A6F66C922D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2008-12-31","until":"2009-03-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 1,774,000,000 United States dollar\", as of 2008-12-31 (until 2009-03-31). Claim clm_10C37649975D, https://asof.is/claim/clm_10C37649975D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_10C37649975D","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"1,774,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_10C37649975D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-03-01"}},{"date":"2008-12-31","until":"2009-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 5,214,000,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_3327385ED8BC, https://asof.is/claim/clm_3327385ED8BC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_3327385ED8BC","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"5,214,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3327385ED8BC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2009, filed 2010-03-01"}},{"date":"2008-12-31","until":"2009-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 4,052,000,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_4826D0123EC0, https://asof.is/claim/clm_4826D0123EC0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_4826D0123EC0","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"4,052,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4826D0123EC0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2009, filed 2010-03-01"}},{"date":"2008-12-31","until":"2009-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 15,003,000,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_52AE9BB2B908, https://asof.is/claim/clm_52AE9BB2B908, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_52AE9BB2B908","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"15,003,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_52AE9BB2B908","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2009, filed 2010-03-01"}},{"date":"2008-12-31","until":"2009-06-30","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 36,427,000,000 United States dollar\", as of 2008-12-31 (until 2009-06-30). Claim clm_84388ADC01D3, https://asof.is/claim/clm_84388ADC01D3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_84388ADC01D3","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"36,427,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_84388ADC01D3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2009, filed 2010-03-01"}},{"date":"2008-12-31","until":"2009-06-30","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 20,885,000,000 United States dollar\", as of 2008-12-31 (until 2009-06-30). Claim clm_AF67FFE7C117, https://asof.is/claim/clm_AF67FFE7C117, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_AF67FFE7C117","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"20,885,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AF67FFE7C117","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2009, filed 2010-03-01"}},{"date":"2009-03-31","until":"2009-06-30","published":"2010-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 2,777,000,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_23946C33E856, https://asof.is/claim/clm_23946C33E856, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510112950/0001193125-10-112950-index.htm.","url":"https://asof.is/claim/clm_23946C33E856","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,777,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_23946C33E856","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2010, filed 2010-05-07"}},{"date":"2009-03-31","until":"2009-06-30","published":"2010-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,321,000,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_6609F02715B5, https://asof.is/claim/clm_6609F02715B5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510112950/0001193125-10-112950-index.htm.","url":"https://asof.is/claim/clm_6609F02715B5","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,321,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6609F02715B5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2010, filed 2010-05-07"}},{"date":"2009-03-31","until":"2009-06-30","published":"2010-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,019,000,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_928390BED923, https://asof.is/claim/clm_928390BED923, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510112950/0001193125-10-112950-index.htm.","url":"https://asof.is/claim/clm_928390BED923","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,019,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_928390BED923","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2010, filed 2010-05-07"}},{"date":"2009-03-31","until":"2009-06-30","published":"2010-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 3,308,000,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_E30E52778B73, https://asof.is/claim/clm_E30E52778B73, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510112950/0001193125-10-112950-index.htm.","url":"https://asof.is/claim/clm_E30E52778B73","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"3,308,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E30E52778B73","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2010, filed 2010-05-07"}},{"date":"2009-04-02","until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen x username: Amgen\", as of 2009-04-02. Claim clm_683636E2586E, https://asof.is/claim/clm_683636E2586E, accessed 2026-11-08. Source: https://www.wikidata.org/wiki/Q470517.","url":"https://asof.is/claim/clm_683636E2586E","accessed":"2026-11-08"},"kind":"other","predicate":"x_username","value":"Amgen","status":"unverified","assertable":false,"why_not":"unverified","id":"clm_683636E2586E","evidence":{"by":"own-site","on":"2026-11-08","quote":"http://www.twitter.com/amgen","url":"http://www.amgen.com/"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 2,968,000,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_06EAF5224086, https://asof.is/claim/clm_06EAF5224086, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509169378/0001193125-09-169378-index.htm.","url":"https://asof.is/claim/clm_06EAF5224086","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,968,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_06EAF5224086","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2009, filed 2009-08-10"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,269,000,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_1D9A473B7296, https://asof.is/claim/clm_1D9A473B7296, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509169378/0001193125-09-169378-index.htm.","url":"https://asof.is/claim/clm_1D9A473B7296","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,269,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1D9A473B7296","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2009, filed 2009-08-10"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 38,840,000,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_8A50591E1758, https://asof.is/claim/clm_8A50591E1758, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509169378/0001193125-09-169378-index.htm.","url":"https://asof.is/claim/clm_8A50591E1758","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"38,840,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8A50591E1758","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2009, filed 2009-08-10"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,457,000,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_A972FFF57CA8, https://asof.is/claim/clm_A972FFF57CA8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509169378/0001193125-09-169378-index.htm.","url":"https://asof.is/claim/clm_A972FFF57CA8","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,457,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A972FFF57CA8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2009, filed 2009-08-10"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 21,360,000,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_BF452CEA40BB, https://asof.is/claim/clm_BF452CEA40BB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509169378/0001193125-09-169378-index.htm.","url":"https://asof.is/claim/clm_BF452CEA40BB","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"21,360,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BF452CEA40BB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2009, filed 2009-08-10"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 3,713,000,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_C0FD4A4DBDE5, https://asof.is/claim/clm_C0FD4A4DBDE5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509169378/0001193125-09-169378-index.htm.","url":"https://asof.is/claim/clm_C0FD4A4DBDE5","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"3,713,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C0FD4A4DBDE5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2009, filed 2009-08-10"}},{"date":"2009-08-03","until":"2009-11-02","published":"2009-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 1,015,476,612 shares\", as of 2009-08-03 (until 2009-11-02). Claim clm_83B59A7440D5, https://asof.is/claim/clm_83B59A7440D5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509169378/0001193125-09-169378-index.htm.","url":"https://asof.is/claim/clm_83B59A7440D5","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,015,476,612 shares","status":"superseded","assertable":true,"id":"clm_83B59A7440D5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2009, filed 2009-08-10"}},{"date":"2009-09-30","until":"2009-12-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,577,000,000 United States dollar\", as of 2009-09-30 (until 2009-12-31). Claim clm_099BDC522C6D, https://asof.is/claim/clm_099BDC522C6D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509227739/0001193125-09-227739-index.htm.","url":"https://asof.is/claim/clm_099BDC522C6D","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,577,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_099BDC522C6D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2009-09-30","until":"2010-03-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,605,000,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_8A1A7F8B1FAB, https://asof.is/claim/clm_8A1A7F8B1FAB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509227739/0001193125-09-227739-index.htm.","url":"https://asof.is/claim/clm_8A1A7F8B1FAB","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,605,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8A1A7F8B1FAB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2009-09-30","until":"2009-12-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 40,940,000,000 United States dollar\", as of 2009-09-30 (until 2009-12-31). Claim clm_960D1E6B27F0, https://asof.is/claim/clm_960D1E6B27F0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509227739/0001193125-09-227739-index.htm.","url":"https://asof.is/claim/clm_960D1E6B27F0","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"40,940,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_960D1E6B27F0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2009-09-30","until":"2010-03-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 3,812,000,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_AC30B5A349EC, https://asof.is/claim/clm_AC30B5A349EC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509227739/0001193125-09-227739-index.htm.","url":"https://asof.is/claim/clm_AC30B5A349EC","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"3,812,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AC30B5A349EC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2009-09-30","until":"2010-03-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,386,000,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_B8CC66F883EA, https://asof.is/claim/clm_B8CC66F883EA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509227739/0001193125-09-227739-index.htm.","url":"https://asof.is/claim/clm_B8CC66F883EA","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,386,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B8CC66F883EA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2009-09-30","until":"2009-12-31","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 22,858,000,000 United States dollar\", as of 2009-09-30 (until 2009-12-31). Claim clm_D33321EF3A62, https://asof.is/claim/clm_D33321EF3A62, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509227739/0001193125-09-227739-index.htm.","url":"https://asof.is/claim/clm_D33321EF3A62","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"22,858,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D33321EF3A62","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2009-11-02","until":"2010-02-12","published":"2009-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 1,012,138,434 shares\", as of 2009-11-02 (until 2010-02-12). Claim clm_A4143E50C193, https://asof.is/claim/clm_A4143E50C193, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312509227739/0001193125-09-227739-index.htm.","url":"https://asof.is/claim/clm_A4143E50C193","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,012,138,434 shares","status":"superseded","assertable":true,"id":"clm_A4143E50C193","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2009, filed 2009-11-06"}},{"date":"2009-12-31","until":"2010-03-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 2,884,000,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_3007B813C9B4, https://asof.is/claim/clm_3007B813C9B4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_3007B813C9B4","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,884,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3007B813C9B4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-03-01"}},{"date":"2009-12-31","until":"2010-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 5,506,000,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_46A559E6C041, https://asof.is/claim/clm_46A559E6C041, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_46A559E6C041","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"5,506,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_46A559E6C041","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2009, filed 2010-03-01"}},{"date":"2009-12-31","until":"2010-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 4,605,000,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_78DDCE0217FE, https://asof.is/claim/clm_78DDCE0217FE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_78DDCE0217FE","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"4,605,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_78DDCE0217FE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2009, filed 2010-03-01"}},{"date":"2009-12-31","until":"2010-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 14,642,000,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_B7B415A6CD44, https://asof.is/claim/clm_B7B415A6CD44, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_B7B415A6CD44","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"14,642,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B7B415A6CD44","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2009, filed 2010-03-01"}},{"date":"2009-12-31","until":"2010-03-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 22,667,000,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_DBA659E53482, https://asof.is/claim/clm_DBA659E53482, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_DBA659E53482","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"22,667,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DBA659E53482","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2009, filed 2010-03-01"}},{"date":"2009-12-31","until":"2010-03-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 39,629,000,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_FD45F1550892, https://asof.is/claim/clm_FD45F1550892, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_FD45F1550892","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"39,629,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FD45F1550892","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2009, filed 2010-03-01"}},{"date":"2010-02-12","until":"2010-05-03","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 979,301,627 shares\", as of 2010-02-12 (until 2010-05-03). Claim clm_4C0262AA6F8C, https://asof.is/claim/clm_4C0262AA6F8C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510044311/0001193125-10-044311-index.htm.","url":"https://asof.is/claim/clm_4C0262AA6F8C","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"979,301,627 shares","status":"superseded","assertable":true,"id":"clm_4C0262AA6F8C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2009, filed 2010-03-01"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 3,592,000,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_0468DD568B92, https://asof.is/claim/clm_0468DD568B92, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510112950/0001193125-10-112950-index.htm.","url":"https://asof.is/claim/clm_0468DD568B92","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"3,592,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0468DD568B92","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2010, filed 2010-05-07"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 2,266,000,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_66B8EB012276, https://asof.is/claim/clm_66B8EB012276, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510112950/0001193125-10-112950-index.htm.","url":"https://asof.is/claim/clm_66B8EB012276","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,266,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_66B8EB012276","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2010, filed 2010-05-07"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,167,000,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_9969F416755C, https://asof.is/claim/clm_9969F416755C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510112950/0001193125-10-112950-index.htm.","url":"https://asof.is/claim/clm_9969F416755C","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,167,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9969F416755C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2010, filed 2010-05-07"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 40,366,000,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_A1DE406B5E7E, https://asof.is/claim/clm_A1DE406B5E7E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510112950/0001193125-10-112950-index.htm.","url":"https://asof.is/claim/clm_A1DE406B5E7E","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"40,366,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A1DE406B5E7E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2010, filed 2010-05-07"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,481,000,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_AD3F260E35C2, https://asof.is/claim/clm_AD3F260E35C2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510112950/0001193125-10-112950-index.htm.","url":"https://asof.is/claim/clm_AD3F260E35C2","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,481,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AD3F260E35C2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2010, filed 2010-05-07"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 22,339,000,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_F7BBC59E66C1, https://asof.is/claim/clm_F7BBC59E66C1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510112950/0001193125-10-112950-index.htm.","url":"https://asof.is/claim/clm_F7BBC59E66C1","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"22,339,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F7BBC59E66C1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2010, filed 2010-05-07"}},{"date":"2010-05-03","until":"2010-07-30","published":"2010-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 957,938,383 shares\", as of 2010-05-03 (until 2010-07-30). Claim clm_718FD5DF2CAF, https://asof.is/claim/clm_718FD5DF2CAF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312510112950/0001193125-10-112950-index.htm.","url":"https://asof.is/claim/clm_718FD5DF2CAF","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"957,938,383 shares","status":"superseded","assertable":true,"id":"clm_718FD5DF2CAF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2010, filed 2010-05-07"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,517,000,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_14CFAC59EFA9, https://asof.is/claim/clm_14CFAC59EFA9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012310074870/0000950123-10-074870-index.htm.","url":"https://asof.is/claim/clm_14CFAC59EFA9","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,517,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_14CFAC59EFA9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2010, filed 2010-08-09"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,202,000,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_5A82BDA9230D, https://asof.is/claim/clm_5A82BDA9230D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012310074870/0000950123-10-074870-index.htm.","url":"https://asof.is/claim/clm_5A82BDA9230D","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,202,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5A82BDA9230D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2010, filed 2010-08-09"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 3,804,000,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_623DCF66B2AC, https://asof.is/claim/clm_623DCF66B2AC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012310074870/0000950123-10-074870-index.htm.","url":"https://asof.is/claim/clm_623DCF66B2AC","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"3,804,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_623DCF66B2AC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2010, filed 2010-08-09"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 23,170,000,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_70DC668489EA, https://asof.is/claim/clm_70DC668489EA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012310074870/0000950123-10-074870-index.htm.","url":"https://asof.is/claim/clm_70DC668489EA","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"23,170,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_70DC668489EA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2010, filed 2010-08-09"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 1,712,000,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_8100A4FAF341, https://asof.is/claim/clm_8100A4FAF341, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012310074870/0000950123-10-074870-index.htm.","url":"https://asof.is/claim/clm_8100A4FAF341","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"1,712,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8100A4FAF341","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2010, filed 2010-08-09"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 40,800,000,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_E2811DD805A8, https://asof.is/claim/clm_E2811DD805A8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012310074870/0000950123-10-074870-index.htm.","url":"https://asof.is/claim/clm_E2811DD805A8","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"40,800,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E2811DD805A8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2010, filed 2010-08-09"}},{"date":"2010-07-30","until":"2010-10-29","published":"2010-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 958,474,477 shares\", as of 2010-07-30 (until 2010-10-29). Claim clm_6D323A1AD7AE, https://asof.is/claim/clm_6D323A1AD7AE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012310074870/0000950123-10-074870-index.htm.","url":"https://asof.is/claim/clm_6D323A1AD7AE","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"958,474,477 shares","status":"superseded","assertable":true,"id":"clm_6D323A1AD7AE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2010, filed 2010-08-09"}},{"date":"2010-09-30","until":"2010-12-31","published":"2010-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 43,534,000,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_19765841AC5F, https://asof.is/claim/clm_19765841AC5F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012310102391/0000950123-10-102391-index.htm.","url":"https://asof.is/claim/clm_19765841AC5F","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"43,534,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_19765841AC5F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2010, filed 2010-11-08"}},{"date":"2010-09-30","until":"2011-03-31","published":"2010-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 3,816,000,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_1E3DCB2075FA, https://asof.is/claim/clm_1E3DCB2075FA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012310102391/0000950123-10-102391-index.htm.","url":"https://asof.is/claim/clm_1E3DCB2075FA","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"3,816,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1E3DCB2075FA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2010, filed 2010-11-08"}},{"date":"2010-09-30","until":"2010-12-31","published":"2010-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 24,071,000,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_40DAD67567CD, https://asof.is/claim/clm_40DAD67567CD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012310102391/0000950123-10-102391-index.htm.","url":"https://asof.is/claim/clm_40DAD67567CD","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"24,071,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_40DAD67567CD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2010, filed 2010-11-08"}},{"date":"2010-09-30","until":"2010-12-31","published":"2010-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 2,951,000,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_7B2497997F4E, https://asof.is/claim/clm_7B2497997F4E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012310102391/0000950123-10-102391-index.htm.","url":"https://asof.is/claim/clm_7B2497997F4E","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,951,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7B2497997F4E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2010, filed 2010-11-08"}},{"date":"2010-09-30","until":"2011-03-31","published":"2010-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,236,000,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_B0E17E7BDD6B, https://asof.is/claim/clm_B0E17E7BDD6B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012310102391/0000950123-10-102391-index.htm.","url":"https://asof.is/claim/clm_B0E17E7BDD6B","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,236,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B0E17E7BDD6B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2010, filed 2010-11-08"}},{"date":"2010-09-30","until":"2011-03-31","published":"2010-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,479,000,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_CAB7E6C967C3, https://asof.is/claim/clm_CAB7E6C967C3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012310102391/0000950123-10-102391-index.htm.","url":"https://asof.is/claim/clm_CAB7E6C967C3","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,479,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CAB7E6C967C3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2010, filed 2010-11-08"}},{"date":"2010-10-29","until":"2011-02-11","published":"2010-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 944,815,396 shares\", as of 2010-10-29 (until 2011-02-11). Claim clm_5E708B99CEDB, https://asof.is/claim/clm_5E708B99CEDB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012310102391/0000950123-10-102391-index.htm.","url":"https://asof.is/claim/clm_5E708B99CEDB","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"944,815,396 shares","status":"superseded","assertable":true,"id":"clm_5E708B99CEDB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2010, filed 2010-11-08"}},{"date":"2010-12-31","until":"2011-12-31","published":"2011-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 15,053,000,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_21002187AEE3, https://asof.is/claim/clm_21002187AEE3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311018800/0000950123-11-018800-index.htm.","url":"https://asof.is/claim/clm_21002187AEE3","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"15,053,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_21002187AEE3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2010, filed 2011-02-25"}},{"date":"2010-12-31","until":"2011-12-31","published":"2011-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 5,545,000,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_2282EE661302, https://asof.is/claim/clm_2282EE661302, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311018800/0000950123-11-018800-index.htm.","url":"https://asof.is/claim/clm_2282EE661302","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"5,545,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2282EE661302","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2010, filed 2011-02-25"}},{"date":"2010-12-31","until":"2011-12-31","published":"2011-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 4,627,000,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_A36EA59B9520, https://asof.is/claim/clm_A36EA59B9520, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311018800/0000950123-11-018800-index.htm.","url":"https://asof.is/claim/clm_A36EA59B9520","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"4,627,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A36EA59B9520","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2010, filed 2011-02-25"}},{"date":"2010-12-31","until":"2011-03-31","published":"2011-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,287,000,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_BBB0BE58C057, https://asof.is/claim/clm_BBB0BE58C057, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311018800/0000950123-11-018800-index.htm.","url":"https://asof.is/claim/clm_BBB0BE58C057","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,287,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BBB0BE58C057","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2010, filed 2011-02-25"}},{"date":"2010-12-31","until":"2011-03-31","published":"2011-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 43,486,000,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_CA6A5441CDCF, https://asof.is/claim/clm_CA6A5441CDCF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311018800/0000950123-11-018800-index.htm.","url":"https://asof.is/claim/clm_CA6A5441CDCF","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"43,486,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CA6A5441CDCF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2010, filed 2011-02-25"}},{"date":"2010-12-31","until":"2011-03-31","published":"2011-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 23,944,000,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_ED303315F19F, https://asof.is/claim/clm_ED303315F19F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311018800/0000950123-11-018800-index.htm.","url":"https://asof.is/claim/clm_ED303315F19F","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"23,944,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ED303315F19F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2010, filed 2011-02-25"}},{"date":"2011-02-11","until":"2011-04-29","published":"2011-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 932,452,902 shares\", as of 2011-02-11 (until 2011-04-29). Claim clm_2D844BCDB1A9, https://asof.is/claim/clm_2D844BCDB1A9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311018800/0000950123-11-018800-index.htm.","url":"https://asof.is/claim/clm_2D844BCDB1A9","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"932,452,902 shares","status":"superseded","assertable":true,"id":"clm_2D844BCDB1A9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2010, filed 2011-02-25"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,293,000,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_087D410B4794, https://asof.is/claim/clm_087D410B4794, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311048073/0000950123-11-048073-index.htm.","url":"https://asof.is/claim/clm_087D410B4794","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,293,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_087D410B4794","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2011, filed 2011-05-10"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 3,706,000,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_5C7EB0130754, https://asof.is/claim/clm_5C7EB0130754, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311048073/0000950123-11-048073-index.htm.","url":"https://asof.is/claim/clm_5C7EB0130754","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"3,706,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5C7EB0130754","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2011, filed 2011-05-10"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 42,714,000,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_6C5A646418EB, https://asof.is/claim/clm_6C5A646418EB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311048073/0000950123-11-048073-index.htm.","url":"https://asof.is/claim/clm_6C5A646418EB","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"42,714,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6C5A646418EB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2011, filed 2011-05-10"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 1,266,000,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_8218A755F248, https://asof.is/claim/clm_8218A755F248, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311048073/0000950123-11-048073-index.htm.","url":"https://asof.is/claim/clm_8218A755F248","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"1,266,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8218A755F248","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2011, filed 2011-05-10"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 24,984,000,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_8B2C132F4605, https://asof.is/claim/clm_8B2C132F4605, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311048073/0000950123-11-048073-index.htm.","url":"https://asof.is/claim/clm_8B2C132F4605","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"24,984,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8B2C132F4605","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2011, filed 2011-05-10"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,125,000,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_D713C582BE0E, https://asof.is/claim/clm_D713C582BE0E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311048073/0000950123-11-048073-index.htm.","url":"https://asof.is/claim/clm_D713C582BE0E","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,125,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D713C582BE0E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2011, filed 2011-05-10"}},{"date":"2011-04-29","until":"2011-07-27","published":"2011-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 929,730,507 shares\", as of 2011-04-29 (until 2011-07-27). Claim clm_E1D7B78E1C33, https://asof.is/claim/clm_E1D7B78E1C33, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311048073/0000950123-11-048073-index.htm.","url":"https://asof.is/claim/clm_E1D7B78E1C33","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"929,730,507 shares","status":"superseded","assertable":true,"id":"clm_E1D7B78E1C33","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2011, filed 2011-05-10"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,332,000,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_010C5F53DEFB, https://asof.is/claim/clm_010C5F53DEFB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311074348/0000950123-11-074348-index.htm.","url":"https://asof.is/claim/clm_010C5F53DEFB","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,332,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_010C5F53DEFB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2011, filed 2011-08-08"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 5,998,000,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_13EE0E401521, https://asof.is/claim/clm_13EE0E401521, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311074348/0000950123-11-074348-index.htm.","url":"https://asof.is/claim/clm_13EE0E401521","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"5,998,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_13EE0E401521","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2011, filed 2011-08-08"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 3,959,000,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_5FE67E316722, https://asof.is/claim/clm_5FE67E316722, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311074348/0000950123-11-074348-index.htm.","url":"https://asof.is/claim/clm_5FE67E316722","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"3,959,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5FE67E316722","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2011, filed 2011-08-08"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 25,614,000,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_67DA709539BB, https://asof.is/claim/clm_67DA709539BB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311074348/0000950123-11-074348-index.htm.","url":"https://asof.is/claim/clm_67DA709539BB","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"25,614,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_67DA709539BB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2011, filed 2011-08-08"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,170,000,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_6E8F27E2EA0D, https://asof.is/claim/clm_6E8F27E2EA0D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311074348/0000950123-11-074348-index.htm.","url":"https://asof.is/claim/clm_6E8F27E2EA0D","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,170,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6E8F27E2EA0D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2011, filed 2011-08-08"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 46,936,000,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_C21B53A4E862, https://asof.is/claim/clm_C21B53A4E862, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311074348/0000950123-11-074348-index.htm.","url":"https://asof.is/claim/clm_C21B53A4E862","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"46,936,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C21B53A4E862","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2011, filed 2011-08-08"}},{"date":"2011-07-27","until":"2011-10-26","published":"2011-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 924,091,356 shares\", as of 2011-07-27 (until 2011-10-26). Claim clm_DB95FD72A669, https://asof.is/claim/clm_DB95FD72A669, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000095012311074348/0000950123-11-074348-index.htm.","url":"https://asof.is/claim/clm_DB95FD72A669","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"924,091,356 shares","status":"superseded","assertable":true,"id":"clm_DB95FD72A669","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2011, filed 2011-08-08"}},{"date":"2011-09-30","until":"2011-12-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 23,553,000,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_1B908EDA7C06, https://asof.is/claim/clm_1B908EDA7C06, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312511296147/0001193125-11-296147-index.htm.","url":"https://asof.is/claim/clm_1B908EDA7C06","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"23,553,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1B908EDA7C06","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2011, filed 2011-11-04"}},{"date":"2011-09-30","until":"2012-03-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 3,944,000,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_296C33E5B63E, https://asof.is/claim/clm_296C33E5B63E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312511296147/0001193125-11-296147-index.htm.","url":"https://asof.is/claim/clm_296C33E5B63E","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"3,944,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_296C33E5B63E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2011, filed 2011-11-04"}},{"date":"2011-09-30","until":"2011-12-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 45,765,000,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_4D9D4E243B38, https://asof.is/claim/clm_4D9D4E243B38, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312511296147/0001193125-11-296147-index.htm.","url":"https://asof.is/claim/clm_4D9D4E243B38","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"45,765,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4D9D4E243B38","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2011, filed 2011-11-04"}},{"date":"2011-09-30","until":"2011-12-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,891,000,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_787BD95A43CF, https://asof.is/claim/clm_787BD95A43CF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312511296147/0001193125-11-296147-index.htm.","url":"https://asof.is/claim/clm_787BD95A43CF","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,891,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_787BD95A43CF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2011, filed 2011-11-04"}},{"date":"2011-09-30","until":"2012-03-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 525,000,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_8E08DF4BFFD6, https://asof.is/claim/clm_8E08DF4BFFD6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312511296147/0001193125-11-296147-index.htm.","url":"https://asof.is/claim/clm_8E08DF4BFFD6","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"525,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8E08DF4BFFD6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2011, filed 2011-11-04"}},{"date":"2011-09-30","until":"2012-03-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 454,000,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_EBFAA5FF45E6, https://asof.is/claim/clm_EBFAA5FF45E6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312511296147/0001193125-11-296147-index.htm.","url":"https://asof.is/claim/clm_EBFAA5FF45E6","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"454,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EBFAA5FF45E6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2011, filed 2011-11-04"}},{"date":"2011-10-26","until":"2012-02-10","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 876,544,275 shares\", as of 2011-10-26 (until 2012-02-10). Claim clm_D1EFB8E701BD, https://asof.is/claim/clm_D1EFB8E701BD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312511296147/0001193125-11-296147-index.htm.","url":"https://asof.is/claim/clm_D1EFB8E701BD","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"876,544,275 shares","status":"superseded","assertable":true,"id":"clm_D1EFB8E701BD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2011, filed 2011-11-04"}},{"date":"2011-12-31","until":"2012-03-31","published":"2012-02-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 6,946,000,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_6D27166168D8, https://asof.is/claim/clm_6D27166168D8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512086670/0001193125-12-086670-index.htm.","url":"https://asof.is/claim/clm_6D27166168D8","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"6,946,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6D27166168D8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2011, filed 2012-02-29"}},{"date":"2011-12-31","until":"2012-12-31","published":"2012-02-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 3,683,000,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_77675AD86D11, https://asof.is/claim/clm_77675AD86D11, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512086670/0001193125-12-086670-index.htm.","url":"https://asof.is/claim/clm_77675AD86D11","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"3,683,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_77675AD86D11","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2011, filed 2012-02-29"}},{"date":"2011-12-31","until":"2012-12-31","published":"2012-02-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 15,582,000,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_C7A9E438A984, https://asof.is/claim/clm_C7A9E438A984, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512086670/0001193125-12-086670-index.htm.","url":"https://asof.is/claim/clm_C7A9E438A984","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"15,582,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C7A9E438A984","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2011, filed 2012-02-29"}},{"date":"2011-12-31","until":"2012-03-31","published":"2012-02-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 19,029,000,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_DF80452A7941, https://asof.is/claim/clm_DF80452A7941, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512086670/0001193125-12-086670-index.htm.","url":"https://asof.is/claim/clm_DF80452A7941","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"19,029,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DF80452A7941","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2011, filed 2012-02-29"}},{"date":"2011-12-31","until":"2012-12-31","published":"2012-02-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 4,312,000,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_E05A3DDD94DD, https://asof.is/claim/clm_E05A3DDD94DD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512086670/0001193125-12-086670-index.htm.","url":"https://asof.is/claim/clm_E05A3DDD94DD","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"4,312,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E05A3DDD94DD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2011, filed 2012-02-29"}},{"date":"2011-12-31","until":"2012-03-31","published":"2012-02-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 48,871,000,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_FCCCD0433A56, https://asof.is/claim/clm_FCCCD0433A56, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512086670/0001193125-12-086670-index.htm.","url":"https://asof.is/claim/clm_FCCCD0433A56","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"48,871,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FCCCD0433A56","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2011, filed 2012-02-29"}},{"date":"2012-02-10","until":"2012-04-26","published":"2012-02-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 791,432,134 shares\", as of 2012-02-10 (until 2012-04-26). Claim clm_814F8DBF99DF, https://asof.is/claim/clm_814F8DBF99DF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512086670/0001193125-12-086670-index.htm.","url":"https://asof.is/claim/clm_814F8DBF99DF","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"791,432,134 shares","status":"superseded","assertable":true,"id":"clm_814F8DBF99DF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2011, filed 2012-02-29"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 4,207,000,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_1146A0E24CD4, https://asof.is/claim/clm_1146A0E24CD4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512216282/0001193125-12-216282-index.htm.","url":"https://asof.is/claim/clm_1146A0E24CD4","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"4,207,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1146A0E24CD4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2012, filed 2012-05-08"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,477,000,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_148D97D70B0C, https://asof.is/claim/clm_148D97D70B0C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512216282/0001193125-12-216282-index.htm.","url":"https://asof.is/claim/clm_148D97D70B0C","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,477,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_148D97D70B0C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2012, filed 2012-05-08"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 4,048,000,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_2763B8997D8B, https://asof.is/claim/clm_2763B8997D8B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512216282/0001193125-12-216282-index.htm.","url":"https://asof.is/claim/clm_2763B8997D8B","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"4,048,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2763B8997D8B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2012, filed 2012-05-08"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 18,874,000,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_3F3775EC0C14, https://asof.is/claim/clm_3F3775EC0C14, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512216282/0001193125-12-216282-index.htm.","url":"https://asof.is/claim/clm_3F3775EC0C14","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"18,874,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3F3775EC0C14","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2012, filed 2012-05-08"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,184,000,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_B28859B14384, https://asof.is/claim/clm_B28859B14384, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512216282/0001193125-12-216282-index.htm.","url":"https://asof.is/claim/clm_B28859B14384","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,184,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B28859B14384","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2012, filed 2012-05-08"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 49,250,000,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_EEC207B785D0, https://asof.is/claim/clm_EEC207B785D0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512216282/0001193125-12-216282-index.htm.","url":"https://asof.is/claim/clm_EEC207B785D0","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"49,250,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EEC207B785D0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2012, filed 2012-05-08"}},{"date":"2012-04-26","until":"2012-07-25","published":"2012-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 777,707,877 shares\", as of 2012-04-26 (until 2012-07-25). Claim clm_70560450A8A4, https://asof.is/claim/clm_70560450A8A4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512216282/0001193125-12-216282-index.htm.","url":"https://asof.is/claim/clm_70560450A8A4","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"777,707,877 shares","status":"superseded","assertable":true,"id":"clm_70560450A8A4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2012, filed 2012-05-08"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 5,849,000,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_03B54912F3E2, https://asof.is/claim/clm_03B54912F3E2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512344279/0001193125-12-344279-index.htm.","url":"https://asof.is/claim/clm_03B54912F3E2","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"5,849,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_03B54912F3E2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2012, filed 2012-08-08"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,266,000,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_376CEF6833C7, https://asof.is/claim/clm_376CEF6833C7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512344279/0001193125-12-344279-index.htm.","url":"https://asof.is/claim/clm_376CEF6833C7","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,266,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_376CEF6833C7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2012, filed 2012-08-08"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,589,000,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_45C687484B85, https://asof.is/claim/clm_45C687484B85, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512344279/0001193125-12-344279-index.htm.","url":"https://asof.is/claim/clm_45C687484B85","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,589,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_45C687484B85","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2012, filed 2012-08-08"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 19,239,000,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_5B76104742F7, https://asof.is/claim/clm_5B76104742F7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512344279/0001193125-12-344279-index.htm.","url":"https://asof.is/claim/clm_5B76104742F7","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"19,239,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5B76104742F7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2012, filed 2012-08-08"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 52,226,000,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_A28B5FEC066F, https://asof.is/claim/clm_A28B5FEC066F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512344279/0001193125-12-344279-index.htm.","url":"https://asof.is/claim/clm_A28B5FEC066F","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"52,226,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A28B5FEC066F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2012, filed 2012-08-08"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 4,477,000,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_D4DC1453EF41, https://asof.is/claim/clm_D4DC1453EF41, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512344279/0001193125-12-344279-index.htm.","url":"https://asof.is/claim/clm_D4DC1453EF41","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"4,477,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D4DC1453EF41","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2012, filed 2012-08-08"}},{"date":"2012-07-25","until":"2012-10-29","published":"2012-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 770,768,879 shares\", as of 2012-07-25 (until 2012-10-29). Claim clm_540E74003993, https://asof.is/claim/clm_540E74003993, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000119312512344279/0001193125-12-344279-index.htm.","url":"https://asof.is/claim/clm_540E74003993","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"770,768,879 shares","status":"superseded","assertable":true,"id":"clm_540E74003993","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2012, filed 2012-08-08"}},{"date":"2012-09-30","until":"2013-03-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,423,000,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_39DD16EEE4D1, https://asof.is/claim/clm_39DD16EEE4D1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530512003469/0001445305-12-003469-index.htm.","url":"https://asof.is/claim/clm_39DD16EEE4D1","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,423,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_39DD16EEE4D1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2012, filed 2012-11-06"}},{"date":"2012-09-30","until":"2013-03-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 4,319,000,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_5BA2730341DC, https://asof.is/claim/clm_5BA2730341DC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530512003469/0001445305-12-003469-index.htm.","url":"https://asof.is/claim/clm_5BA2730341DC","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"4,319,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5BA2730341DC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2012, filed 2012-11-06"}},{"date":"2012-09-30","until":"2013-03-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,107,000,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_8CA0968C8B53, https://asof.is/claim/clm_8CA0968C8B53, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530512003469/0001445305-12-003469-index.htm.","url":"https://asof.is/claim/clm_8CA0968C8B53","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,107,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8CA0968C8B53","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2012, filed 2012-11-06"}},{"date":"2012-09-30","until":"2012-12-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 5,823,000,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_DA97E5CF2AF5, https://asof.is/claim/clm_DA97E5CF2AF5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530512003469/0001445305-12-003469-index.htm.","url":"https://asof.is/claim/clm_DA97E5CF2AF5","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"5,823,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DA97E5CF2AF5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2012, filed 2012-11-06"}},{"date":"2012-09-30","until":"2012-12-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 19,902,000,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_DB1DDF8CC003, https://asof.is/claim/clm_DB1DDF8CC003, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530512003469/0001445305-12-003469-index.htm.","url":"https://asof.is/claim/clm_DB1DDF8CC003","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"19,902,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DB1DDF8CC003","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2012, filed 2012-11-06"}},{"date":"2012-09-30","until":"2012-12-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 55,448,000,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_ED89BA9D10C9, https://asof.is/claim/clm_ED89BA9D10C9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530512003469/0001445305-12-003469-index.htm.","url":"https://asof.is/claim/clm_ED89BA9D10C9","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"55,448,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ED89BA9D10C9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2012, filed 2012-11-06"}},{"date":"2012-10-29","until":"2013-02-19","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 767,355,259 shares\", as of 2012-10-29 (until 2013-02-19). Claim clm_6365725354C1, https://asof.is/claim/clm_6365725354C1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530512003469/0001445305-12-003469-index.htm.","url":"https://asof.is/claim/clm_6365725354C1","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"767,355,259 shares","status":"superseded","assertable":true,"id":"clm_6365725354C1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2012, filed 2012-11-06"}},{"date":"2012-12-31","until":"2013-03-31","published":"2013-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,257,000,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_05AF32DE89A0, https://asof.is/claim/clm_05AF32DE89A0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530513000364/0001445305-13-000364-index.htm.","url":"https://asof.is/claim/clm_05AF32DE89A0","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,257,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_05AF32DE89A0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2012, filed 2013-02-27"}},{"date":"2012-12-31","until":"2013-12-31","published":"2013-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 5,577,000,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_18B2DC42BBCB, https://asof.is/claim/clm_18B2DC42BBCB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530513000364/0001445305-13-000364-index.htm.","url":"https://asof.is/claim/clm_18B2DC42BBCB","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"5,577,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_18B2DC42BBCB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2012, filed 2013-02-27"}},{"date":"2012-12-31","until":"2013-03-31","published":"2013-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 54,298,000,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_3519CC2C0B29, https://asof.is/claim/clm_3519CC2C0B29, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530513000364/0001445305-13-000364-index.htm.","url":"https://asof.is/claim/clm_3519CC2C0B29","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"54,298,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3519CC2C0B29","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2012, filed 2013-02-27"}},{"date":"2012-12-31","until":"2013-03-31","published":"2013-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 19,060,000,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_4CC7E97EBEA6, https://asof.is/claim/clm_4CC7E97EBEA6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530513000364/0001445305-13-000364-index.htm.","url":"https://asof.is/claim/clm_4CC7E97EBEA6","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"19,060,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4CC7E97EBEA6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2012, filed 2013-02-27"}},{"date":"2012-12-31","until":"2013-12-31","published":"2013-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 4,345,000,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_84C2CE669D18, https://asof.is/claim/clm_84C2CE669D18, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530513000364/0001445305-13-000364-index.htm.","url":"https://asof.is/claim/clm_84C2CE669D18","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"4,345,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_84C2CE669D18","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2012, filed 2013-02-27"}},{"date":"2012-12-31","until":"2013-12-31","published":"2013-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 17,265,000,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_EC47C2B5A921, https://asof.is/claim/clm_EC47C2B5A921, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530513000364/0001445305-13-000364-index.htm.","url":"https://asof.is/claim/clm_EC47C2B5A921","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"17,265,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EC47C2B5A921","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2012, filed 2013-02-27"}},{"date":"2013-02-19","until":"2013-04-24","published":"2013-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 748,430,018 shares\", as of 2013-02-19 (until 2013-04-24). Claim clm_ACDCA67E4AE4, https://asof.is/claim/clm_ACDCA67E4AE4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530513000364/0001445305-13-000364-index.htm.","url":"https://asof.is/claim/clm_ACDCA67E4AE4","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"748,430,018 shares","status":"superseded","assertable":true,"id":"clm_ACDCA67E4AE4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2012, filed 2013-02-27"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 4,238,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_4DC2460750E0, https://asof.is/claim/clm_4DC2460750E0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530513001107/0001445305-13-001107-index.htm.","url":"https://asof.is/claim/clm_4DC2460750E0","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"4,238,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4DC2460750E0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2013, filed 2013-05-03"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 2,530,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_7A1F93F832FE, https://asof.is/claim/clm_7A1F93F832FE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530513001107/0001445305-13-001107-index.htm.","url":"https://asof.is/claim/clm_7A1F93F832FE","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,530,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7A1F93F832FE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2013, filed 2013-05-03"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,442,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_84DD01B3B35F, https://asof.is/claim/clm_84DD01B3B35F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530513001107/0001445305-13-001107-index.htm.","url":"https://asof.is/claim/clm_84DD01B3B35F","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,442,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_84DD01B3B35F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2013, filed 2013-05-03"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,434,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_8A4D481B9F27, https://asof.is/claim/clm_8A4D481B9F27, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530513001107/0001445305-13-001107-index.htm.","url":"https://asof.is/claim/clm_8A4D481B9F27","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,434,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8A4D481B9F27","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2013, filed 2013-05-03"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 51,640,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_C67140F0772C, https://asof.is/claim/clm_C67140F0772C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530513001107/0001445305-13-001107-index.htm.","url":"https://asof.is/claim/clm_C67140F0772C","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"51,640,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C67140F0772C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2013, filed 2013-05-03"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 19,491,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_D045AE9FFC56, https://asof.is/claim/clm_D045AE9FFC56, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530513001107/0001445305-13-001107-index.htm.","url":"https://asof.is/claim/clm_D045AE9FFC56","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"19,491,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D045AE9FFC56","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2013, filed 2013-05-03"}},{"date":"2013-04-24","until":"2013-07-30","published":"2013-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 749,976,556 shares\", as of 2013-04-24 (until 2013-07-30). Claim clm_E3B8A2E816E8, https://asof.is/claim/clm_E3B8A2E816E8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000144530513001107/0001445305-13-001107-index.htm.","url":"https://asof.is/claim/clm_E3B8A2E816E8","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"749,976,556 shares","status":"superseded","assertable":true,"id":"clm_E3B8A2E816E8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2013, filed 2013-05-03"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,550,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_1DF1A1C609E1, https://asof.is/claim/clm_1DF1A1C609E1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815413000008/0000318154-13-000008-index.htm.","url":"https://asof.is/claim/clm_1DF1A1C609E1","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,550,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1DF1A1C609E1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 5,806,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_2E4B5E4DFAE5, https://asof.is/claim/clm_2E4B5E4DFAE5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815413000008/0000318154-13-000008-index.htm.","url":"https://asof.is/claim/clm_2E4B5E4DFAE5","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"5,806,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2E4B5E4DFAE5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 52,610,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_39B4E0673406, https://asof.is/claim/clm_39B4E0673406, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815413000008/0000318154-13-000008-index.htm.","url":"https://asof.is/claim/clm_39B4E0673406","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"52,610,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_39B4E0673406","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,258,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_890A9BB01DD3, https://asof.is/claim/clm_890A9BB01DD3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815413000008/0000318154-13-000008-index.htm.","url":"https://asof.is/claim/clm_890A9BB01DD3","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,258,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_890A9BB01DD3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 4,679,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_B14B41207FDF, https://asof.is/claim/clm_B14B41207FDF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815413000008/0000318154-13-000008-index.htm.","url":"https://asof.is/claim/clm_B14B41207FDF","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"4,679,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B14B41207FDF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 20,594,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_D15F50A325E7, https://asof.is/claim/clm_D15F50A325E7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815413000008/0000318154-13-000008-index.htm.","url":"https://asof.is/claim/clm_D15F50A325E7","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"20,594,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D15F50A325E7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-07-30","until":"2013-10-22","published":"2013-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 753,356,209 shares\", as of 2013-07-30 (until 2013-10-22). Claim clm_7946AE508D58, https://asof.is/claim/clm_7946AE508D58, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815413000008/0000318154-13-000008-index.htm.","url":"https://asof.is/claim/clm_7946AE508D58","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"753,356,209 shares","status":"superseded","assertable":true,"id":"clm_7946AE508D58","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2013, filed 2013-08-06"}},{"date":"2013-09-30","until":"2014-03-31","published":"2013-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 4,748,000,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_3033018610D0, https://asof.is/claim/clm_3033018610D0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815413000012/0000318154-13-000012-index.htm.","url":"https://asof.is/claim/clm_3033018610D0","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"4,748,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3033018610D0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2013, filed 2013-10-29"}},{"date":"2013-09-30","until":"2013-12-31","published":"2013-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 8,281,000,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_54048E292013, https://asof.is/claim/clm_54048E292013, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815413000012/0000318154-13-000012-index.htm.","url":"https://asof.is/claim/clm_54048E292013","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"8,281,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_54048E292013","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2013, filed 2013-10-29"}},{"date":"2013-09-30","until":"2013-12-31","published":"2013-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 57,073,000,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_76443A277A6C, https://asof.is/claim/clm_76443A277A6C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815413000012/0000318154-13-000012-index.htm.","url":"https://asof.is/claim/clm_76443A277A6C","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"57,073,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_76443A277A6C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2013, filed 2013-10-29"}},{"date":"2013-09-30","until":"2014-03-31","published":"2013-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,688,000,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_B0A9F616BD13, https://asof.is/claim/clm_B0A9F616BD13, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815413000012/0000318154-13-000012-index.htm.","url":"https://asof.is/claim/clm_B0A9F616BD13","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,688,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B0A9F616BD13","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2013, filed 2013-10-29"}},{"date":"2013-09-30","until":"2014-03-31","published":"2013-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,368,000,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_BF2B62C3B6C9, https://asof.is/claim/clm_BF2B62C3B6C9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815413000012/0000318154-13-000012-index.htm.","url":"https://asof.is/claim/clm_BF2B62C3B6C9","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,368,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BF2B62C3B6C9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2013, filed 2013-10-29"}},{"date":"2013-09-30","until":"2013-12-31","published":"2013-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 21,728,000,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_F959576F5D57, https://asof.is/claim/clm_F959576F5D57, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815413000012/0000318154-13-000012-index.htm.","url":"https://asof.is/claim/clm_F959576F5D57","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"21,728,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F959576F5D57","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2013, filed 2013-10-29"}},{"date":"2013-10-22","until":"2014-02-13","published":"2013-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 754,126,197 shares\", as of 2013-10-22 (until 2014-02-13). Claim clm_FFC4D3147C5E, https://asof.is/claim/clm_FFC4D3147C5E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815413000012/0000318154-13-000012-index.htm.","url":"https://asof.is/claim/clm_FFC4D3147C5E","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"754,126,197 shares","status":"superseded","assertable":true,"id":"clm_FFC4D3147C5E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2013, filed 2013-10-29"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 18,676,000,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_3D7A43128430, https://asof.is/claim/clm_3D7A43128430, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000004/0000318154-14-000004-index.htm.","url":"https://asof.is/claim/clm_3D7A43128430","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"18,676,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3D7A43128430","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2013, filed 2014-02-24"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 5,081,000,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_7D7780676598, https://asof.is/claim/clm_7D7780676598, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000004/0000318154-14-000004-index.htm.","url":"https://asof.is/claim/clm_7D7780676598","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"5,081,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7D7780676598","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2013, filed 2014-02-24"}},{"date":"2013-12-31","until":"2014-03-31","published":"2014-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 66,125,000,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_A0287B4C76BE, https://asof.is/claim/clm_A0287B4C76BE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000004/0000318154-14-000004-index.htm.","url":"https://asof.is/claim/clm_A0287B4C76BE","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"66,125,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A0287B4C76BE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2013, filed 2014-02-24"}},{"date":"2013-12-31","until":"2014-03-31","published":"2014-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,805,000,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_A7F5983DB63E, https://asof.is/claim/clm_A7F5983DB63E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000004/0000318154-14-000004-index.htm.","url":"https://asof.is/claim/clm_A7F5983DB63E","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,805,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A7F5983DB63E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2013, filed 2014-02-24"}},{"date":"2013-12-31","until":"2014-03-31","published":"2014-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 22,096,000,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_CC7EBB14F5AA, https://asof.is/claim/clm_CC7EBB14F5AA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000004/0000318154-14-000004-index.htm.","url":"https://asof.is/claim/clm_CC7EBB14F5AA","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"22,096,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CC7EBB14F5AA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2013, filed 2014-02-24"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 5,867,000,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_D1F7CCF21F2B, https://asof.is/claim/clm_D1F7CCF21F2B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000004/0000318154-14-000004-index.htm.","url":"https://asof.is/claim/clm_D1F7CCF21F2B","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"5,867,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D1F7CCF21F2B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2013, filed 2014-02-24"}},{"date":"2014-02-13","until":"2014-04-22","published":"2014-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 755,007,290 shares\", as of 2014-02-13 (until 2014-04-22). Claim clm_C9B23C443A68, https://asof.is/claim/clm_C9B23C443A68, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000004/0000318154-14-000004-index.htm.","url":"https://asof.is/claim/clm_C9B23C443A68","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"755,007,290 shares","status":"superseded","assertable":true,"id":"clm_C9B23C443A68","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2013, filed 2014-02-24"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,364,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_1C381C3663B1, https://asof.is/claim/clm_1C381C3663B1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000008/0000318154-14-000008-index.htm.","url":"https://asof.is/claim/clm_1C381C3663B1","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,364,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1C381C3663B1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2014, filed 2014-04-30"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 67,004,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_1DC4233C61D6, https://asof.is/claim/clm_1DC4233C61D6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000008/0000318154-14-000008-index.htm.","url":"https://asof.is/claim/clm_1DC4233C61D6","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"67,004,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1DC4233C61D6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2014, filed 2014-04-30"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,073,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_2AFFA5A382C9, https://asof.is/claim/clm_2AFFA5A382C9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000008/0000318154-14-000008-index.htm.","url":"https://asof.is/claim/clm_2AFFA5A382C9","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,073,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2AFFA5A382C9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2014, filed 2014-04-30"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 22,741,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_2F8840B9A878, https://asof.is/claim/clm_2F8840B9A878, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000008/0000318154-14-000008-index.htm.","url":"https://asof.is/claim/clm_2F8840B9A878","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"22,741,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2F8840B9A878","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2014, filed 2014-04-30"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 4,521,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_4A26C5460842, https://asof.is/claim/clm_4A26C5460842, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000008/0000318154-14-000008-index.htm.","url":"https://asof.is/claim/clm_4A26C5460842","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"4,521,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4A26C5460842","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2014, filed 2014-04-30"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,687,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_85F128FF8BDF, https://asof.is/claim/clm_85F128FF8BDF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000008/0000318154-14-000008-index.htm.","url":"https://asof.is/claim/clm_85F128FF8BDF","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,687,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_85F128FF8BDF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2014, filed 2014-04-30"}},{"date":"2014-04-22","until":"2014-07-29","published":"2014-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 757,021,648 shares\", as of 2014-04-22 (until 2014-07-29). Claim clm_37781152ABE8, https://asof.is/claim/clm_37781152ABE8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000008/0000318154-14-000008-index.htm.","url":"https://asof.is/claim/clm_37781152ABE8","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"757,021,648 shares","status":"superseded","assertable":true,"id":"clm_37781152ABE8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2014, filed 2014-04-30"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,547,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_82CA77D552C0, https://asof.is/claim/clm_82CA77D552C0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000017/0000318154-14-000017-index.htm.","url":"https://asof.is/claim/clm_82CA77D552C0","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,547,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_82CA77D552C0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 24,382,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_905DE244F62B, https://asof.is/claim/clm_905DE244F62B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000017/0000318154-14-000017-index.htm.","url":"https://asof.is/claim/clm_905DE244F62B","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"24,382,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_905DE244F62B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,902,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_941927EE0CBF, https://asof.is/claim/clm_941927EE0CBF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000017/0000318154-14-000017-index.htm.","url":"https://asof.is/claim/clm_941927EE0CBF","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,902,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_941927EE0CBF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 69,534,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_CF482D232326, https://asof.is/claim/clm_CF482D232326, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000017/0000318154-14-000017-index.htm.","url":"https://asof.is/claim/clm_CF482D232326","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"69,534,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CF482D232326","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 4,352,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_DA248B5305A9, https://asof.is/claim/clm_DA248B5305A9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000017/0000318154-14-000017-index.htm.","url":"https://asof.is/claim/clm_DA248B5305A9","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"4,352,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DA248B5305A9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,180,000,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_F203C4084F80, https://asof.is/claim/clm_F203C4084F80, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000017/0000318154-14-000017-index.htm.","url":"https://asof.is/claim/clm_F203C4084F80","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,180,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F203C4084F80","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-07-29","until":"2014-10-21","published":"2014-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 759,607,230 shares\", as of 2014-07-29 (until 2014-10-21). Claim clm_8A83A0002048, https://asof.is/claim/clm_8A83A0002048, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000017/0000318154-14-000017-index.htm.","url":"https://asof.is/claim/clm_8A83A0002048","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"759,607,230 shares","status":"superseded","assertable":true,"id":"clm_8A83A0002048","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2014, filed 2014-08-05"}},{"date":"2014-09-30","until":"2014-12-31","published":"2014-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,677,000,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_10CF13C1B54A, https://asof.is/claim/clm_10CF13C1B54A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000022/0000318154-14-000022-index.htm.","url":"https://asof.is/claim/clm_10CF13C1B54A","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,677,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_10CF13C1B54A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2014, filed 2014-10-29"}},{"date":"2014-09-30","until":"2014-12-31","published":"2014-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 25,325,000,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_7580FDD62A85, https://asof.is/claim/clm_7580FDD62A85, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000022/0000318154-14-000022-index.htm.","url":"https://asof.is/claim/clm_7580FDD62A85","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"25,325,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7580FDD62A85","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2014, filed 2014-10-29"}},{"date":"2014-09-30","until":"2014-12-31","published":"2014-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 70,775,000,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_7D37893DF373, https://asof.is/claim/clm_7D37893DF373, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000022/0000318154-14-000022-index.htm.","url":"https://asof.is/claim/clm_7D37893DF373","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"70,775,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7D37893DF373","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2014, filed 2014-10-29"}},{"date":"2014-09-30","until":"2015-03-31","published":"2014-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,244,000,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_A1443987DC93, https://asof.is/claim/clm_A1443987DC93, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000022/0000318154-14-000022-index.htm.","url":"https://asof.is/claim/clm_A1443987DC93","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,244,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A1443987DC93","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2014, filed 2014-10-29"}},{"date":"2014-09-30","until":"2015-03-31","published":"2014-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,466,000,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_F42B8D164D66, https://asof.is/claim/clm_F42B8D164D66, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000022/0000318154-14-000022-index.htm.","url":"https://asof.is/claim/clm_F42B8D164D66","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,466,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F42B8D164D66","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2014, filed 2014-10-29"}},{"date":"2014-09-30","until":"2015-03-31","published":"2014-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,031,000,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_FE2BDD289F38, https://asof.is/claim/clm_FE2BDD289F38, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000022/0000318154-14-000022-index.htm.","url":"https://asof.is/claim/clm_FE2BDD289F38","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,031,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FE2BDD289F38","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2014, filed 2014-10-29"}},{"date":"2014-10-21","until":"2015-02-12","published":"2014-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 760,670,000 shares\", as of 2014-10-21 (until 2015-02-12). Claim clm_93F41910F022, https://asof.is/claim/clm_93F41910F022, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815414000022/0000318154-14-000022-index.htm.","url":"https://asof.is/claim/clm_93F41910F022","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"760,670,000 shares","status":"superseded","assertable":true,"id":"clm_93F41910F022","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2014, filed 2014-10-29"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 5,158,000,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_071C52720059, https://asof.is/claim/clm_071C52720059, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000005/0000318154-15-000005-index.htm.","url":"https://asof.is/claim/clm_071C52720059","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"5,158,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_071C52720059","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2014, filed 2015-02-19"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 20,063,000,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_4F9F8554DED3, https://asof.is/claim/clm_4F9F8554DED3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000005/0000318154-15-000005-index.htm.","url":"https://asof.is/claim/clm_4F9F8554DED3","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"20,063,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4F9F8554DED3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2014, filed 2015-02-19"}},{"date":"2014-12-31","until":"2015-03-31","published":"2015-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 69,009,000,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_554D2AE9FD76, https://asof.is/claim/clm_554D2AE9FD76, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000005/0000318154-15-000005-index.htm.","url":"https://asof.is/claim/clm_554D2AE9FD76","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"69,009,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_554D2AE9FD76","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2014, filed 2015-02-19"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 6,191,000,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_7FEB7D7DF8E7, https://asof.is/claim/clm_7FEB7D7DF8E7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000005/0000318154-15-000005-index.htm.","url":"https://asof.is/claim/clm_7FEB7D7DF8E7","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"6,191,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7FEB7D7DF8E7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2014, filed 2015-02-19"}},{"date":"2014-12-31","until":"2015-03-31","published":"2015-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,731,000,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_BEC2DEF69723, https://asof.is/claim/clm_BEC2DEF69723, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000005/0000318154-15-000005-index.htm.","url":"https://asof.is/claim/clm_BEC2DEF69723","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,731,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BEC2DEF69723","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2014, filed 2015-02-19"}},{"date":"2014-12-31","until":"2015-03-31","published":"2015-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 25,778,000,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_E3E3E7359787, https://asof.is/claim/clm_E3E3E7359787, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000005/0000318154-15-000005-index.htm.","url":"https://asof.is/claim/clm_E3E3E7359787","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"25,778,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E3E3E7359787","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2014, filed 2015-02-19"}},{"date":"2015-02-12","until":"2015-04-20","published":"2015-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 758,861,306 shares\", as of 2015-02-12 (until 2015-04-20). Claim clm_03C8CF5E3CB4, https://asof.is/claim/clm_03C8CF5E3CB4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000005/0000318154-15-000005-index.htm.","url":"https://asof.is/claim/clm_03C8CF5E3CB4","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"758,861,306 shares","status":"superseded","assertable":true,"id":"clm_03C8CF5E3CB4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2014, filed 2015-02-19"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,623,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_0A7CF5308206, https://asof.is/claim/clm_0A7CF5308206, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000010/0000318154-15-000010-index.htm.","url":"https://asof.is/claim/clm_0A7CF5308206","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,623,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0A7CF5308206","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2015, filed 2015-04-27"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 2,864,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_596A841E23FE, https://asof.is/claim/clm_596A841E23FE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000010/0000318154-15-000010-index.htm.","url":"https://asof.is/claim/clm_596A841E23FE","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,864,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_596A841E23FE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2015, filed 2015-04-27"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 26,506,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_771831E45D09, https://asof.is/claim/clm_771831E45D09, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000010/0000318154-15-000010-index.htm.","url":"https://asof.is/claim/clm_771831E45D09","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"26,506,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_771831E45D09","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2015, filed 2015-04-27"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,033,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_C0A999C2E5DE, https://asof.is/claim/clm_C0A999C2E5DE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000010/0000318154-15-000010-index.htm.","url":"https://asof.is/claim/clm_C0A999C2E5DE","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,033,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C0A999C2E5DE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2015, filed 2015-04-27"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,022,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_C47F1D4F30C5, https://asof.is/claim/clm_C47F1D4F30C5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000010/0000318154-15-000010-index.htm.","url":"https://asof.is/claim/clm_C47F1D4F30C5","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,022,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C47F1D4F30C5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2015, filed 2015-04-27"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 68,952,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_DD3641090074, https://asof.is/claim/clm_DD3641090074, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000010/0000318154-15-000010-index.htm.","url":"https://asof.is/claim/clm_DD3641090074","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"68,952,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DD3641090074","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2015, filed 2015-04-27"}},{"date":"2015-04-20","until":"2015-07-28","published":"2015-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 760,323,664 shares\", as of 2015-04-20 (until 2015-07-28). Claim clm_C311BB3AF4EC, https://asof.is/claim/clm_C311BB3AF4EC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000010/0000318154-15-000010-index.htm.","url":"https://asof.is/claim/clm_C311BB3AF4EC","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"760,323,664 shares","status":"superseded","assertable":true,"id":"clm_C311BB3AF4EC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2015, filed 2015-04-27"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,370,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_28F3330C360C, https://asof.is/claim/clm_28F3330C360C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000022/0000318154-15-000022-index.htm.","url":"https://asof.is/claim/clm_28F3330C360C","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,370,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_28F3330C360C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2015, filed 2015-08-05"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,795,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_5851D9252E69, https://asof.is/claim/clm_5851D9252E69, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000022/0000318154-15-000022-index.htm.","url":"https://asof.is/claim/clm_5851D9252E69","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,795,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5851D9252E69","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2015, filed 2015-08-05"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 71,209,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_821821A36787, https://asof.is/claim/clm_821821A36787, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000022/0000318154-15-000022-index.htm.","url":"https://asof.is/claim/clm_821821A36787","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"71,209,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_821821A36787","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2015, filed 2015-08-05"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 27,484,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_C5ED4B615A7E, https://asof.is/claim/clm_C5ED4B615A7E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000022/0000318154-15-000022-index.htm.","url":"https://asof.is/claim/clm_C5ED4B615A7E","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"27,484,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C5ED4B615A7E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2015, filed 2015-08-05"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,653,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_E3112AD96827, https://asof.is/claim/clm_E3112AD96827, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000022/0000318154-15-000022-index.htm.","url":"https://asof.is/claim/clm_E3112AD96827","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,653,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E3112AD96827","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2015, filed 2015-08-05"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,076,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_F0CFF35E1C2C, https://asof.is/claim/clm_F0CFF35E1C2C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000022/0000318154-15-000022-index.htm.","url":"https://asof.is/claim/clm_F0CFF35E1C2C","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,076,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F0CFF35E1C2C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2015, filed 2015-08-05"}},{"date":"2015-07-28","until":"2015-10-27","published":"2015-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 758,250,346 shares\", as of 2015-07-28 (until 2015-10-27). Claim clm_AC443719191E, https://asof.is/claim/clm_AC443719191E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000022/0000318154-15-000022-index.htm.","url":"https://asof.is/claim/clm_AC443719191E","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"758,250,346 shares","status":"superseded","assertable":true,"id":"clm_AC443719191E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2015, filed 2015-08-05"}},{"date":"2015-09-30","until":"2016-03-31","published":"2015-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,863,000,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_1CD07968584F, https://asof.is/claim/clm_1CD07968584F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000025/0000318154-15-000025-index.htm.","url":"https://asof.is/claim/clm_1CD07968584F","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,863,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1CD07968584F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2015, filed 2015-11-02"}},{"date":"2015-09-30","until":"2015-12-31","published":"2015-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 71,869,000,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_397DCD0B0485, https://asof.is/claim/clm_397DCD0B0485, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000025/0000318154-15-000025-index.htm.","url":"https://asof.is/claim/clm_397DCD0B0485","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"71,869,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_397DCD0B0485","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2015, filed 2015-11-02"}},{"date":"2015-09-30","until":"2016-03-31","published":"2015-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,723,000,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_85E7DB9BD8C5, https://asof.is/claim/clm_85E7DB9BD8C5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000025/0000318154-15-000025-index.htm.","url":"https://asof.is/claim/clm_85E7DB9BD8C5","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,723,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_85E7DB9BD8C5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2015, filed 2015-11-02"}},{"date":"2015-09-30","until":"2015-12-31","published":"2015-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 27,967,000,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_92CB2B598E88, https://asof.is/claim/clm_92CB2B598E88, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000025/0000318154-15-000025-index.htm.","url":"https://asof.is/claim/clm_92CB2B598E88","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"27,967,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_92CB2B598E88","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2015, filed 2015-11-02"}},{"date":"2015-09-30","until":"2016-03-31","published":"2015-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,339,000,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_9938617951E0, https://asof.is/claim/clm_9938617951E0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000025/0000318154-15-000025-index.htm.","url":"https://asof.is/claim/clm_9938617951E0","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,339,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9938617951E0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2015, filed 2015-11-02"}},{"date":"2015-09-30","until":"2015-12-31","published":"2015-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,226,000,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_DE022A363AF0, https://asof.is/claim/clm_DE022A363AF0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000025/0000318154-15-000025-index.htm.","url":"https://asof.is/claim/clm_DE022A363AF0","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,226,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DE022A363AF0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2015, filed 2015-11-02"}},{"date":"2015-10-27","until":"2016-02-09","published":"2015-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 754,327,866 shares\", as of 2015-10-27 (until 2016-02-09). Claim clm_7E3142F8191A, https://asof.is/claim/clm_7E3142F8191A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815415000025/0000318154-15-000025-index.htm.","url":"https://asof.is/claim/clm_7E3142F8191A","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"754,327,866 shares","status":"superseded","assertable":true,"id":"clm_7E3142F8191A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2015, filed 2015-11-02"}},{"date":"2015-12-31","until":"2016-03-31","published":"2016-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 71,576,000,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_5116B3B21711, https://asof.is/claim/clm_5116B3B21711, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000031/0000318154-16-000031-index.htm.","url":"https://asof.is/claim/clm_5116B3B21711","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"71,576,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5116B3B21711","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2015, filed 2016-02-16"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 8,470,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_5F24CA9F1236, https://asof.is/claim/clm_5F24CA9F1236, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000031/0000318154-16-000031-index.htm.","url":"https://asof.is/claim/clm_5F24CA9F1236","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"8,470,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5F24CA9F1236","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2015, filed 2016-02-16"}},{"date":"2015-12-31","until":"2016-03-31","published":"2016-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 4,144,000,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_62DBA6442A89, https://asof.is/claim/clm_62DBA6442A89, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000031/0000318154-16-000031-index.htm.","url":"https://asof.is/claim/clm_62DBA6442A89","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"4,144,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_62DBA6442A89","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2015, filed 2016-02-16"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 21,662,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_6460A66923A8, https://asof.is/claim/clm_6460A66923A8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000031/0000318154-16-000031-index.htm.","url":"https://asof.is/claim/clm_6460A66923A8","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"21,662,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6460A66923A8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2015, filed 2016-02-16"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 6,939,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_797A8E0010E4, https://asof.is/claim/clm_797A8E0010E4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000031/0000318154-16-000031-index.htm.","url":"https://asof.is/claim/clm_797A8E0010E4","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"6,939,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_797A8E0010E4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2015, filed 2016-02-16"}},{"date":"2015-12-31","until":"2016-03-31","published":"2016-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 28,083,000,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_94F707C99E20, https://asof.is/claim/clm_94F707C99E20, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000031/0000318154-16-000031-index.htm.","url":"https://asof.is/claim/clm_94F707C99E20","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"28,083,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_94F707C99E20","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2015, filed 2016-02-16"}},{"date":"2016-02-09","until":"2016-04-25","published":"2016-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 752,091,038 shares\", as of 2016-02-09 (until 2016-04-25). Claim clm_9623B7B662B5, https://asof.is/claim/clm_9623B7B662B5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000031/0000318154-16-000031-index.htm.","url":"https://asof.is/claim/clm_9623B7B662B5","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"752,091,038 shares","status":"superseded","assertable":true,"id":"clm_9623B7B662B5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2015, filed 2016-02-16"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,900,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_363FD391E3A4, https://asof.is/claim/clm_363FD391E3A4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000035/0000318154-16-000035-index.htm.","url":"https://asof.is/claim/clm_363FD391E3A4","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,900,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_363FD391E3A4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2016, filed 2016-05-02"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 75,116,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_9006A4E3AEA7, https://asof.is/claim/clm_9006A4E3AEA7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000035/0000318154-16-000035-index.htm.","url":"https://asof.is/claim/clm_9006A4E3AEA7","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"75,116,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9006A4E3AEA7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2016, filed 2016-05-02"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,527,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_9742AA3344DF, https://asof.is/claim/clm_9742AA3344DF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000035/0000318154-16-000035-index.htm.","url":"https://asof.is/claim/clm_9742AA3344DF","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,527,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9742AA3344DF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2016, filed 2016-05-02"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 2,896,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_AC822552ABB6, https://asof.is/claim/clm_AC822552ABB6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000035/0000318154-16-000035-index.htm.","url":"https://asof.is/claim/clm_AC822552ABB6","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,896,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AC822552ABB6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2016, filed 2016-05-02"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,402,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_CB3F23126391, https://asof.is/claim/clm_CB3F23126391, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000035/0000318154-16-000035-index.htm.","url":"https://asof.is/claim/clm_CB3F23126391","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,402,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CB3F23126391","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2016, filed 2016-05-02"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 28,682,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_F89E040E0B16, https://asof.is/claim/clm_F89E040E0B16, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000035/0000318154-16-000035-index.htm.","url":"https://asof.is/claim/clm_F89E040E0B16","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"28,682,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F89E040E0B16","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2016, filed 2016-05-02"}},{"date":"2016-04-25","until":"2016-07-25","published":"2016-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 751,217,078 shares\", as of 2016-04-25 (until 2016-07-25). Claim clm_DACE114B6A42, https://asof.is/claim/clm_DACE114B6A42, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000035/0000318154-16-000035-index.htm.","url":"https://asof.is/claim/clm_DACE114B6A42","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"751,217,078 shares","status":"superseded","assertable":true,"id":"clm_DACE114B6A42","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2016, filed 2016-05-02"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,870,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_1DC1E9754547, https://asof.is/claim/clm_1DC1E9754547, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000046/0000318154-16-000046-index.htm.","url":"https://asof.is/claim/clm_1DC1E9754547","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,870,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1DC1E9754547","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2016, filed 2016-07-29"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,688,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_293E3106D6E2, https://asof.is/claim/clm_293E3106D6E2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000046/0000318154-16-000046-index.htm.","url":"https://asof.is/claim/clm_293E3106D6E2","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,688,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_293E3106D6E2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2016, filed 2016-07-29"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,380,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_D18BB69DF47F, https://asof.is/claim/clm_D18BB69DF47F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000046/0000318154-16-000046-index.htm.","url":"https://asof.is/claim/clm_D18BB69DF47F","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,380,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D18BB69DF47F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2016, filed 2016-07-29"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 75,471,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_D40F2EB93762, https://asof.is/claim/clm_D40F2EB93762, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000046/0000318154-16-000046-index.htm.","url":"https://asof.is/claim/clm_D40F2EB93762","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"75,471,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D40F2EB93762","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2016, filed 2016-07-29"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 2,630,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_E0A3DD098E3C, https://asof.is/claim/clm_E0A3DD098E3C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000046/0000318154-16-000046-index.htm.","url":"https://asof.is/claim/clm_E0A3DD098E3C","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,630,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E0A3DD098E3C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2016, filed 2016-07-29"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 30,133,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_F743D4B5E033, https://asof.is/claim/clm_F743D4B5E033, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000046/0000318154-16-000046-index.htm.","url":"https://asof.is/claim/clm_F743D4B5E033","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"30,133,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F743D4B5E033","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2016, filed 2016-07-29"}},{"date":"2016-07-25","until":"2016-10-24","published":"2016-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 748,360,906 shares\", as of 2016-07-25 (until 2016-10-24). Claim clm_9F5464384718, https://asof.is/claim/clm_9F5464384718, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000046/0000318154-16-000046-index.htm.","url":"https://asof.is/claim/clm_9F5464384718","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"748,360,906 shares","status":"superseded","assertable":true,"id":"clm_9F5464384718","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2016, filed 2016-07-29"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,527,000,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_29CEBD7716C0, https://asof.is/claim/clm_29CEBD7716C0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000053/0000318154-16-000053-index.htm.","url":"https://asof.is/claim/clm_29CEBD7716C0","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,527,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_29CEBD7716C0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2016, filed 2016-10-28"}},{"date":"2016-09-30","until":"2016-12-31","published":"2016-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 78,150,000,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_37FDCE0641B8, https://asof.is/claim/clm_37FDCE0641B8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000053/0000318154-16-000053-index.htm.","url":"https://asof.is/claim/clm_37FDCE0641B8","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"78,150,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_37FDCE0641B8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2016, filed 2016-10-28"}},{"date":"2016-09-30","until":"2016-12-31","published":"2016-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,485,000,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_950B1AD7EAC9, https://asof.is/claim/clm_950B1AD7EAC9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000053/0000318154-16-000053-index.htm.","url":"https://asof.is/claim/clm_950B1AD7EAC9","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,485,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_950B1AD7EAC9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2016, filed 2016-10-28"}},{"date":"2016-09-30","until":"2016-12-31","published":"2016-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 30,773,000,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_99201951EE61, https://asof.is/claim/clm_99201951EE61, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000053/0000318154-16-000053-index.htm.","url":"https://asof.is/claim/clm_99201951EE61","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"30,773,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_99201951EE61","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2016, filed 2016-10-28"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 2,017,000,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_D60223B7773B, https://asof.is/claim/clm_D60223B7773B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000053/0000318154-16-000053-index.htm.","url":"https://asof.is/claim/clm_D60223B7773B","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"2,017,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D60223B7773B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2016, filed 2016-10-28"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,811,000,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_E9FEE791CE06, https://asof.is/claim/clm_E9FEE791CE06, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000053/0000318154-16-000053-index.htm.","url":"https://asof.is/claim/clm_E9FEE791CE06","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,811,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E9FEE791CE06","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2016, filed 2016-10-28"}},{"date":"2016-10-24","until":"2017-02-09","published":"2016-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 743,922,473 shares\", as of 2016-10-24 (until 2017-02-09). Claim clm_632362E81884, https://asof.is/claim/clm_632362E81884, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815416000053/0000318154-16-000053-index.htm.","url":"https://asof.is/claim/clm_632362E81884","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"743,922,473 shares","status":"superseded","assertable":true,"id":"clm_632362E81884","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2016, filed 2016-10-28"}},{"date":"2016-12-31","until":"2017-12-31","published":"2017-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 22,991,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_33F31087C483, https://asof.is/claim/clm_33F31087C483, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000004/0000318154-17-000004-index.htm.","url":"https://asof.is/claim/clm_33F31087C483","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"22,991,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_33F31087C483","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2016, filed 2017-02-14"}},{"date":"2016-12-31","until":"2017-03-31","published":"2017-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 77,626,000,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_7C10FDC2C635, https://asof.is/claim/clm_7C10FDC2C635, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000004/0000318154-17-000004-index.htm.","url":"https://asof.is/claim/clm_7C10FDC2C635","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"77,626,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7C10FDC2C635","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2016, filed 2017-02-14"}},{"date":"2016-12-31","until":"2017-12-31","published":"2017-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 9,794,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_9C393580212E, https://asof.is/claim/clm_9C393580212E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000004/0000318154-17-000004-index.htm.","url":"https://asof.is/claim/clm_9C393580212E","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"9,794,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9C393580212E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2016, filed 2017-02-14"}},{"date":"2016-12-31","until":"2017-12-31","published":"2017-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 7,722,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_A5BF59D89483, https://asof.is/claim/clm_A5BF59D89483, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000004/0000318154-17-000004-index.htm.","url":"https://asof.is/claim/clm_A5BF59D89483","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"7,722,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A5BF59D89483","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2016, filed 2017-02-14"}},{"date":"2016-12-31","until":"2017-03-31","published":"2017-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 29,875,000,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_BF0D3030F73E, https://asof.is/claim/clm_BF0D3030F73E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000004/0000318154-17-000004-index.htm.","url":"https://asof.is/claim/clm_BF0D3030F73E","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"29,875,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BF0D3030F73E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2016, filed 2017-02-14"}},{"date":"2016-12-31","until":"2017-03-31","published":"2017-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,241,000,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_E62A544C9923, https://asof.is/claim/clm_E62A544C9923, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000004/0000318154-17-000004-index.htm.","url":"https://asof.is/claim/clm_E62A544C9923","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,241,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E62A544C9923","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2016, filed 2017-02-14"}},{"date":"2017-02-09","until":"2017-04-18","published":"2017-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 736,452,791 shares\", as of 2017-02-09 (until 2017-04-18). Claim clm_7DBD3E835AB8, https://asof.is/claim/clm_7DBD3E835AB8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000004/0000318154-17-000004-index.htm.","url":"https://asof.is/claim/clm_7DBD3E835AB8","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"736,452,791 shares","status":"superseded","assertable":true,"id":"clm_7DBD3E835AB8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2016, filed 2017-02-14"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,464,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_3B1946434040, https://asof.is/claim/clm_3B1946434040, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000009/0000318154-17-000009-index.htm.","url":"https://asof.is/claim/clm_3B1946434040","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,464,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3B1946434040","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2017, filed 2017-04-27"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 2,071,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_7D03D58A08B9, https://asof.is/claim/clm_7D03D58A08B9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000009/0000318154-17-000009-index.htm.","url":"https://asof.is/claim/clm_7D03D58A08B9","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"2,071,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7D03D58A08B9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2017, filed 2017-04-27"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,358,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_8E4F00DBED65, https://asof.is/claim/clm_8E4F00DBED65, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000009/0000318154-17-000009-index.htm.","url":"https://asof.is/claim/clm_8E4F00DBED65","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,358,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8E4F00DBED65","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2017, filed 2017-04-27"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 77,862,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_A52F1A8099CB, https://asof.is/claim/clm_A52F1A8099CB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000009/0000318154-17-000009-index.htm.","url":"https://asof.is/claim/clm_A52F1A8099CB","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"77,862,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A52F1A8099CB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2017, filed 2017-04-27"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 30,637,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_DD2379CF3330, https://asof.is/claim/clm_DD2379CF3330, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000009/0000318154-17-000009-index.htm.","url":"https://asof.is/claim/clm_DD2379CF3330","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"30,637,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DD2379CF3330","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2017, filed 2017-04-27"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,591,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_F7F0878C88D4, https://asof.is/claim/clm_F7F0878C88D4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000009/0000318154-17-000009-index.htm.","url":"https://asof.is/claim/clm_F7F0878C88D4","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,591,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F7F0878C88D4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2017, filed 2017-04-27"}},{"date":"2017-04-18","until":"2017-07-18","published":"2017-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 735,399,128 shares\", as of 2017-04-18 (until 2017-07-18). Claim clm_64EE6A24BD4B, https://asof.is/claim/clm_64EE6A24BD4B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000009/0000318154-17-000009-index.htm.","url":"https://asof.is/claim/clm_64EE6A24BD4B","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"735,399,128 shares","status":"superseded","assertable":true,"id":"clm_64EE6A24BD4B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2017, filed 2017-04-27"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 79,587,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_174E9062ADCC, https://asof.is/claim/clm_174E9062ADCC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000021/0000318154-17-000021-index.htm.","url":"https://asof.is/claim/clm_174E9062ADCC","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"79,587,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_174E9062ADCC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2017, filed 2017-07-26"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 2,151,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_2970793B064E, https://asof.is/claim/clm_2970793B064E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000021/0000318154-17-000021-index.htm.","url":"https://asof.is/claim/clm_2970793B064E","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"2,151,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2970793B064E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2017, filed 2017-07-26"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,698,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_4DB5BAF9C86F, https://asof.is/claim/clm_4DB5BAF9C86F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000021/0000318154-17-000021-index.htm.","url":"https://asof.is/claim/clm_4DB5BAF9C86F","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,698,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4DB5BAF9C86F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2017, filed 2017-07-26"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 2,629,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_88AF69313798, https://asof.is/claim/clm_88AF69313798, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000021/0000318154-17-000021-index.htm.","url":"https://asof.is/claim/clm_88AF69313798","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,629,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_88AF69313798","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2017, filed 2017-07-26"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,810,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_8C784DFC08A6, https://asof.is/claim/clm_8C784DFC08A6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000021/0000318154-17-000021-index.htm.","url":"https://asof.is/claim/clm_8C784DFC08A6","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,810,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8C784DFC08A6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2017, filed 2017-07-26"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 31,722,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_E6437073D865, https://asof.is/claim/clm_E6437073D865, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000021/0000318154-17-000021-index.htm.","url":"https://asof.is/claim/clm_E6437073D865","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"31,722,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E6437073D865","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2017, filed 2017-07-26"}},{"date":"2017-07-18","until":"2017-10-17","published":"2017-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 729,674,773 shares\", as of 2017-07-18 (until 2017-10-17). Claim clm_4DCBBE171CD3, https://asof.is/claim/clm_4DCBBE171CD3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000021/0000318154-17-000021-index.htm.","url":"https://asof.is/claim/clm_4DCBBE171CD3","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"729,674,773 shares","status":"superseded","assertable":true,"id":"clm_4DCBBE171CD3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2017, filed 2017-07-26"}},{"date":"2017-09-30","until":"2017-12-31","published":"2017-10-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,000,000,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_0BA540E04C08, https://asof.is/claim/clm_0BA540E04C08, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000027/0000318154-17-000027-index.htm.","url":"https://asof.is/claim/clm_0BA540E04C08","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,000,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0BA540E04C08","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2017, filed 2017-10-26"}},{"date":"2017-09-30","until":"2018-03-31","published":"2017-10-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,773,000,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_3BAD99E25427, https://asof.is/claim/clm_3BAD99E25427, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000027/0000318154-17-000027-index.htm.","url":"https://asof.is/claim/clm_3BAD99E25427","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,773,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3BAD99E25427","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2017, filed 2017-10-26"}},{"date":"2017-09-30","until":"2017-12-31","published":"2017-10-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 32,229,000,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_4C3C0E706B52, https://asof.is/claim/clm_4C3C0E706B52, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000027/0000318154-17-000027-index.htm.","url":"https://asof.is/claim/clm_4C3C0E706B52","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"32,229,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4C3C0E706B52","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2017, filed 2017-10-26"}},{"date":"2017-09-30","until":"2017-12-31","published":"2017-10-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 80,331,000,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_643B856508E4, https://asof.is/claim/clm_643B856508E4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000027/0000318154-17-000027-index.htm.","url":"https://asof.is/claim/clm_643B856508E4","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"80,331,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_643B856508E4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2017, filed 2017-10-26"}},{"date":"2017-09-30","until":"2018-03-31","published":"2017-10-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,439,000,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_A7F81572ADB3, https://asof.is/claim/clm_A7F81572ADB3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000027/0000318154-17-000027-index.htm.","url":"https://asof.is/claim/clm_A7F81572ADB3","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,439,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A7F81572ADB3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2017, filed 2017-10-26"}},{"date":"2017-09-30","until":"2018-03-31","published":"2017-10-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 2,021,000,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_B82AB1C3159B, https://asof.is/claim/clm_B82AB1C3159B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000027/0000318154-17-000027-index.htm.","url":"https://asof.is/claim/clm_B82AB1C3159B","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"2,021,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B82AB1C3159B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2017, filed 2017-10-26"}},{"date":"2017-10-17","until":"2018-02-09","published":"2017-10-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 725,910,575 shares\", as of 2017-10-17 (until 2018-02-09). Claim clm_A8C70ACAF4DA, https://asof.is/claim/clm_A8C70ACAF4DA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815417000027/0000318154-17-000027-index.htm.","url":"https://asof.is/claim/clm_A8C70ACAF4DA","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"725,910,575 shares","status":"superseded","assertable":true,"id":"clm_A8C70ACAF4DA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2017, filed 2017-10-26"}},{"date":"2017-12-31","until":"2018-03-31","published":"2018-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 3,800,000,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_16369A4AC42E, https://asof.is/claim/clm_16369A4AC42E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000004/0000318154-18-000004-index.htm.","url":"https://asof.is/claim/clm_16369A4AC42E","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,800,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_16369A4AC42E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2017, filed 2018-02-13"}},{"date":"2017-12-31","until":"2018-12-31","published":"2018-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 1,979,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_2C7BDDED6E27, https://asof.is/claim/clm_2C7BDDED6E27, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000004/0000318154-18-000004-index.htm.","url":"https://asof.is/claim/clm_2C7BDDED6E27","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"1,979,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2C7BDDED6E27","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2017, filed 2018-02-13"}},{"date":"2017-12-31","until":"2018-12-31","published":"2018-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 9,973,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_3FE1CD809E20, https://asof.is/claim/clm_3FE1CD809E20, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000004/0000318154-18-000004-index.htm.","url":"https://asof.is/claim/clm_3FE1CD809E20","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"9,973,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3FE1CD809E20","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2017, filed 2018-02-13"}},{"date":"2017-12-31","until":"2018-03-31","published":"2018-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 79,954,000,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_718943D64327, https://asof.is/claim/clm_718943D64327, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000004/0000318154-18-000004-index.htm.","url":"https://asof.is/claim/clm_718943D64327","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"79,954,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_718943D64327","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2017, filed 2018-02-13"}},{"date":"2017-12-31","until":"2018-03-31","published":"2018-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 25,241,000,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_C6D997322E62, https://asof.is/claim/clm_C6D997322E62, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000004/0000318154-18-000004-index.htm.","url":"https://asof.is/claim/clm_C6D997322E62","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"25,241,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C6D997322E62","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2017, filed 2018-02-13"}},{"date":"2017-12-31","until":"2018-12-31","published":"2018-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 22,849,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_D4EEBB71EC7D, https://asof.is/claim/clm_D4EEBB71EC7D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000004/0000318154-18-000004-index.htm.","url":"https://asof.is/claim/clm_D4EEBB71EC7D","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"22,849,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D4EEBB71EC7D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2017, filed 2018-02-13"}},{"date":"2018-02-09","until":"2018-04-18","published":"2018-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 720,562,246 shares\", as of 2018-02-09 (until 2018-04-18). Claim clm_96402624AA53, https://asof.is/claim/clm_96402624AA53, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000004/0000318154-18-000004-index.htm.","url":"https://asof.is/claim/clm_96402624AA53","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"720,562,246 shares","status":"superseded","assertable":true,"id":"clm_96402624AA53","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2017, filed 2018-02-13"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-04-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 2,311,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_0C7BF65A9CC8, https://asof.is/claim/clm_0C7BF65A9CC8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000008/0000318154-18-000008-index.htm.","url":"https://asof.is/claim/clm_0C7BF65A9CC8","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"2,311,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0C7BF65A9CC8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2018, filed 2018-04-25"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-04-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 9,741,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_2D8F2FC9E463, https://asof.is/claim/clm_2D8F2FC9E463, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000008/0000318154-18-000008-index.htm.","url":"https://asof.is/claim/clm_2D8F2FC9E463","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"9,741,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2D8F2FC9E463","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2018, filed 2018-04-25"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-04-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 15,620,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_3940E74F06F0, https://asof.is/claim/clm_3940E74F06F0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000008/0000318154-18-000008-index.htm.","url":"https://asof.is/claim/clm_3940E74F06F0","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"15,620,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3940E74F06F0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2018, filed 2018-04-25"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-04-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 71,164,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_3E0AC172DD20, https://asof.is/claim/clm_3E0AC172DD20, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000008/0000318154-18-000008-index.htm.","url":"https://asof.is/claim/clm_3E0AC172DD20","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"71,164,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3E0AC172DD20","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2018, filed 2018-04-25"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-04-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,554,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_756E88917872, https://asof.is/claim/clm_756E88917872, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000008/0000318154-18-000008-index.htm.","url":"https://asof.is/claim/clm_756E88917872","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,554,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_756E88917872","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2018, filed 2018-04-25"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-04-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,726,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_9C5726C18879, https://asof.is/claim/clm_9C5726C18879, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000008/0000318154-18-000008-index.htm.","url":"https://asof.is/claim/clm_9C5726C18879","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,726,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9C5726C18879","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2018, filed 2018-04-25"}},{"date":"2018-04-18","until":"2018-07-18","published":"2018-04-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 661,706,007 shares\", as of 2018-04-18 (until 2018-07-18). Claim clm_185AD84BC290, https://asof.is/claim/clm_185AD84BC290, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000008/0000318154-18-000008-index.htm.","url":"https://asof.is/claim/clm_185AD84BC290","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"661,706,007 shares","status":"superseded","assertable":true,"id":"clm_185AD84BC290","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2018, filed 2018-04-25"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-07-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 10,131,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_0DBEED486A33, https://asof.is/claim/clm_0DBEED486A33, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000015/0000318154-18-000015-index.htm.","url":"https://asof.is/claim/clm_0DBEED486A33","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"10,131,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0DBEED486A33","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2018, filed 2018-07-27"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-07-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 2,296,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_2220944AC708, https://asof.is/claim/clm_2220944AC708, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000015/0000318154-18-000015-index.htm.","url":"https://asof.is/claim/clm_2220944AC708","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"2,296,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2220944AC708","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2018, filed 2018-07-27"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-07-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,832,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_2D8C36C0626B, https://asof.is/claim/clm_2D8C36C0626B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000015/0000318154-18-000015-index.htm.","url":"https://asof.is/claim/clm_2D8C36C0626B","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,832,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2D8C36C0626B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2018, filed 2018-07-27"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-07-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 14,909,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_8A7A5177FE47, https://asof.is/claim/clm_8A7A5177FE47, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000015/0000318154-18-000015-index.htm.","url":"https://asof.is/claim/clm_8A7A5177FE47","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,909,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8A7A5177FE47","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2018, filed 2018-07-27"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-07-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 6,059,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_AAF52E028DB6, https://asof.is/claim/clm_AAF52E028DB6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000015/0000318154-18-000015-index.htm.","url":"https://asof.is/claim/clm_AAF52E028DB6","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,059,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AAF52E028DB6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2018, filed 2018-07-27"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-07-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 67,684,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_E8B932265B26, https://asof.is/claim/clm_E8B932265B26, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000015/0000318154-18-000015-index.htm.","url":"https://asof.is/claim/clm_E8B932265B26","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"67,684,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E8B932265B26","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2018, filed 2018-07-27"}},{"date":"2018-07-18","until":"2018-10-24","published":"2018-07-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 647,272,067 shares\", as of 2018-07-18 (until 2018-10-24). Claim clm_0F1D20A7154A, https://asof.is/claim/clm_0F1D20A7154A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000015/0000318154-18-000015-index.htm.","url":"https://asof.is/claim/clm_0F1D20A7154A","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"647,272,067 shares","status":"superseded","assertable":true,"id":"clm_0F1D20A7154A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2018, filed 2018-07-27"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 14,349,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_08B4799386AF, https://asof.is/claim/clm_08B4799386AF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000022/0000318154-18-000022-index.htm.","url":"https://asof.is/claim/clm_08B4799386AF","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,349,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_08B4799386AF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2018, filed 2018-10-31"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 67,333,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_0AD0B0D546EB, https://asof.is/claim/clm_0AD0B0D546EB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000022/0000318154-18-000022-index.htm.","url":"https://asof.is/claim/clm_0AD0B0D546EB","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"67,333,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0AD0B0D546EB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2018, filed 2018-10-31"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,859,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_17338F01F53F, https://asof.is/claim/clm_17338F01F53F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000022/0000318154-18-000022-index.htm.","url":"https://asof.is/claim/clm_17338F01F53F","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,859,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_17338F01F53F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2018, filed 2018-10-31"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 11,956,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_226AFDC7ECB0, https://asof.is/claim/clm_226AFDC7ECB0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000022/0000318154-18-000022-index.htm.","url":"https://asof.is/claim/clm_226AFDC7ECB0","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"11,956,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_226AFDC7ECB0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2018, filed 2018-10-31"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,323,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_3A298D9EC5BB, https://asof.is/claim/clm_3A298D9EC5BB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000022/0000318154-18-000022-index.htm.","url":"https://asof.is/claim/clm_3A298D9EC5BB","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,323,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3A298D9EC5BB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2018, filed 2018-10-31"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,904,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_87A5042FAB0D, https://asof.is/claim/clm_87A5042FAB0D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000022/0000318154-18-000022-index.htm.","url":"https://asof.is/claim/clm_87A5042FAB0D","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,904,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_87A5042FAB0D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2018, filed 2018-10-31"}},{"date":"2018-10-24","until":"2019-02-07","published":"2018-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 637,219,244 shares\", as of 2018-10-24 (until 2019-02-07). Claim clm_709BAAA1A0C7, https://asof.is/claim/clm_709BAAA1A0C7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815418000022/0000318154-18-000022-index.htm.","url":"https://asof.is/claim/clm_709BAAA1A0C7","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"637,219,244 shares","status":"superseded","assertable":true,"id":"clm_709BAAA1A0C7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2018, filed 2018-10-31"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 10,263,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_1E3D48FD1C81, https://asof.is/claim/clm_1E3D48FD1C81, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000008/0000318154-19-000008-index.htm.","url":"https://asof.is/claim/clm_1E3D48FD1C81","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"10,263,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1E3D48FD1C81","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2018, filed 2019-02-13"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 6,945,000,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_24506D67CAC5, https://asof.is/claim/clm_24506D67CAC5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000008/0000318154-19-000008-index.htm.","url":"https://asof.is/claim/clm_24506D67CAC5","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"6,945,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_24506D67CAC5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2018, filed 2019-02-13"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 23,747,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_340FB654E4B9, https://asof.is/claim/clm_340FB654E4B9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000008/0000318154-19-000008-index.htm.","url":"https://asof.is/claim/clm_340FB654E4B9","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"23,747,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_340FB654E4B9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2018, filed 2019-02-13"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 66,416,000,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_4B925E62643E, https://asof.is/claim/clm_4B925E62643E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000008/0000318154-19-000008-index.htm.","url":"https://asof.is/claim/clm_4B925E62643E","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"66,416,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4B925E62643E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2018, filed 2019-02-13"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 8,394,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_7F963F7A3BF5, https://asof.is/claim/clm_7F963F7A3BF5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000008/0000318154-19-000008-index.htm.","url":"https://asof.is/claim/clm_7F963F7A3BF5","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"8,394,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7F963F7A3BF5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2018, filed 2019-02-13"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 12,500,000,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_84D402BD4390, https://asof.is/claim/clm_84D402BD4390, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000008/0000318154-19-000008-index.htm.","url":"https://asof.is/claim/clm_84D402BD4390","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"12,500,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_84D402BD4390","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2018, filed 2019-02-13"}},{"date":"2019-02-07","until":"2019-04-24","published":"2019-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 622,278,034 shares\", as of 2019-02-07 (until 2019-04-24). Claim clm_CE1D1BBB65EB, https://asof.is/claim/clm_CE1D1BBB65EB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000008/0000318154-19-000008-index.htm.","url":"https://asof.is/claim/clm_CE1D1BBB65EB","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"622,278,034 shares","status":"superseded","assertable":true,"id":"clm_CE1D1BBB65EB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2018, filed 2019-02-13"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 63,997,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_1431EBB4BEA3, https://asof.is/claim/clm_1431EBB4BEA3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000018/0000318154-19-000018-index.htm.","url":"https://asof.is/claim/clm_1431EBB4BEA3","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"63,997,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1431EBB4BEA3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,557,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_9AD858C121AE, https://asof.is/claim/clm_9AD858C121AE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000018/0000318154-19-000018-index.htm.","url":"https://asof.is/claim/clm_9AD858C121AE","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,557,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9AD858C121AE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,472,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_ADA46DB14C4E, https://asof.is/claim/clm_ADA46DB14C4E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000018/0000318154-19-000018-index.htm.","url":"https://asof.is/claim/clm_ADA46DB14C4E","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,472,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ADA46DB14C4E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 10,832,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_B43E99166EDA, https://asof.is/claim/clm_B43E99166EDA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000018/0000318154-19-000018-index.htm.","url":"https://asof.is/claim/clm_B43E99166EDA","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"10,832,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B43E99166EDA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,992,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_BA7043500A6A, https://asof.is/claim/clm_BA7043500A6A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000018/0000318154-19-000018-index.htm.","url":"https://asof.is/claim/clm_BA7043500A6A","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,992,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BA7043500A6A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 7,358,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_D20943685A4B, https://asof.is/claim/clm_D20943685A4B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000018/0000318154-19-000018-index.htm.","url":"https://asof.is/claim/clm_D20943685A4B","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"7,358,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D20943685A4B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2019-04-24","until":"2019-07-24","published":"2019-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 609,935,682 shares\", as of 2019-04-24 (until 2019-07-24). Claim clm_226B9B63D1EC, https://asof.is/claim/clm_226B9B63D1EC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000018/0000318154-19-000018-index.htm.","url":"https://asof.is/claim/clm_226B9B63D1EC","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"609,935,682 shares","status":"superseded","assertable":true,"id":"clm_226B9B63D1EC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2019, filed 2019-05-01"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,871,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_0261B36A9FD9, https://asof.is/claim/clm_0261B36A9FD9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000037/0000318154-19-000037-index.htm.","url":"https://asof.is/claim/clm_0261B36A9FD9","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,871,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0261B36A9FD9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 10,794,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_15DDEC9FE673, https://asof.is/claim/clm_15DDEC9FE673, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000037/0000318154-19-000037-index.htm.","url":"https://asof.is/claim/clm_15DDEC9FE673","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"10,794,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_15DDEC9FE673","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 2,179,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_206CA4F50FEA, https://asof.is/claim/clm_206CA4F50FEA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000037/0000318154-19-000037-index.htm.","url":"https://asof.is/claim/clm_206CA4F50FEA","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"2,179,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_206CA4F50FEA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,678,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_352EE42890C4, https://asof.is/claim/clm_352EE42890C4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000037/0000318154-19-000037-index.htm.","url":"https://asof.is/claim/clm_352EE42890C4","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,678,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_352EE42890C4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 59,373,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_47FB0FC871FE, https://asof.is/claim/clm_47FB0FC871FE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000037/0000318154-19-000037-index.htm.","url":"https://asof.is/claim/clm_47FB0FC871FE","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"59,373,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_47FB0FC871FE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 5,525,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_E548AD354AFD, https://asof.is/claim/clm_E548AD354AFD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000037/0000318154-19-000037-index.htm.","url":"https://asof.is/claim/clm_E548AD354AFD","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"5,525,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E548AD354AFD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2019-07-24","until":"2019-10-23","published":"2019-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 599,701,222 shares\", as of 2019-07-24 (until 2019-10-23). Claim clm_FC64A72BD0A5, https://asof.is/claim/clm_FC64A72BD0A5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000037/0000318154-19-000037-index.htm.","url":"https://asof.is/claim/clm_FC64A72BD0A5","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"599,701,222 shares","status":"superseded","assertable":true,"id":"clm_FC64A72BD0A5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2019, filed 2019-07-31"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,968,000,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_2207406F389E, https://asof.is/claim/clm_2207406F389E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000046/0000318154-19-000046-index.htm.","url":"https://asof.is/claim/clm_2207406F389E","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,968,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2207406F389E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2019, filed 2019-10-30"}},{"date":"2019-09-30","until":"2019-12-31","published":"2019-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 10,927,000,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_348858F3E721, https://asof.is/claim/clm_348858F3E721, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000046/0000318154-19-000046-index.htm.","url":"https://asof.is/claim/clm_348858F3E721","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"10,927,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_348858F3E721","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2019, filed 2019-10-30"}},{"date":"2019-09-30","until":"2019-12-31","published":"2019-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 59,535,000,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_5C58544C5DCC, https://asof.is/claim/clm_5C58544C5DCC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000046/0000318154-19-000046-index.htm.","url":"https://asof.is/claim/clm_5C58544C5DCC","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"59,535,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5C58544C5DCC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2019, filed 2019-10-30"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,476,000,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_7E3BD1C19435, https://asof.is/claim/clm_7E3BD1C19435, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000046/0000318154-19-000046-index.htm.","url":"https://asof.is/claim/clm_7E3BD1C19435","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,476,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7E3BD1C19435","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2019, filed 2019-10-30"}},{"date":"2019-09-30","until":"2019-12-31","published":"2019-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 11,415,000,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_DB87B36EEE9A, https://asof.is/claim/clm_DB87B36EEE9A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000046/0000318154-19-000046-index.htm.","url":"https://asof.is/claim/clm_DB87B36EEE9A","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"11,415,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DB87B36EEE9A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2019, filed 2019-10-30"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,737,000,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_E2FB86DE7982, https://asof.is/claim/clm_E2FB86DE7982, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000046/0000318154-19-000046-index.htm.","url":"https://asof.is/claim/clm_E2FB86DE7982","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,737,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E2FB86DE7982","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2019, filed 2019-10-30"}},{"date":"2019-10-23","until":"2020-02-06","published":"2019-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 594,183,541 shares\", as of 2019-10-23 (until 2020-02-06). Claim clm_C38259D1A5D3, https://asof.is/claim/clm_C38259D1A5D3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815419000046/0000318154-19-000046-index.htm.","url":"https://asof.is/claim/clm_C38259D1A5D3","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"594,183,541 shares","status":"superseded","assertable":true,"id":"clm_C38259D1A5D3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2019, filed 2019-10-30"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 9,674,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_10BA888AB580, https://asof.is/claim/clm_10BA888AB580, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/0000318154-20-000017-index.htm.","url":"https://asof.is/claim/clm_10BA888AB580","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"9,674,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_10BA888AB580","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2019, filed 2020-02-12"}},{"date":"2019-12-31","until":"2020-03-31","published":"2020-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 9,673,000,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_183536BBBD61, https://asof.is/claim/clm_183536BBBD61, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/0000318154-20-000017-index.htm.","url":"https://asof.is/claim/clm_183536BBBD61","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"9,673,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_183536BBBD61","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2019, filed 2020-02-12"}},{"date":"2019-12-31","until":"2020-03-31","published":"2020-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 59,707,000,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_37D604168646, https://asof.is/claim/clm_37D604168646, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/0000318154-20-000017-index.htm.","url":"https://asof.is/claim/clm_37D604168646","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"59,707,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_37D604168646","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2019, filed 2020-02-12"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 7,842,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_43A49B7648F8, https://asof.is/claim/clm_43A49B7648F8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/0000318154-20-000017-index.htm.","url":"https://asof.is/claim/clm_43A49B7648F8","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"7,842,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_43A49B7648F8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2019, filed 2020-02-12"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 23,362,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_8EF1DBCB836F, https://asof.is/claim/clm_8EF1DBCB836F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/0000318154-20-000017-index.htm.","url":"https://asof.is/claim/clm_8EF1DBCB836F","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"23,362,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8EF1DBCB836F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2019, filed 2020-02-12"}},{"date":"2019-12-31","until":"2020-03-31","published":"2020-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 6,037,000,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_FAAD62580296, https://asof.is/claim/clm_FAAD62580296, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/0000318154-20-000017-index.htm.","url":"https://asof.is/claim/clm_FAAD62580296","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"6,037,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FAAD62580296","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2019, filed 2020-02-12"}},{"date":"2020-02-06","until":"2020-04-27","published":"2020-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 589,806,819 shares\", as of 2020-02-06 (until 2020-04-27). Claim clm_AB83B8B5713B, https://asof.is/claim/clm_AB83B8B5713B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000017/0000318154-20-000017-index.htm.","url":"https://asof.is/claim/clm_AB83B8B5713B","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"589,806,819 shares","status":"superseded","assertable":true,"id":"clm_AB83B8B5713B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2019, filed 2020-02-12"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 61,669,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_1DF598E8A627, https://asof.is/claim/clm_1DF598E8A627, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000031/0000318154-20-000031-index.htm.","url":"https://asof.is/claim/clm_1DF598E8A627","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"61,669,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1DF598E8A627","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2020, filed 2020-05-01"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 7,687,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_3D6D73A86504, https://asof.is/claim/clm_3D6D73A86504, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000031/0000318154-20-000031-index.htm.","url":"https://asof.is/claim/clm_3D6D73A86504","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"7,687,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3D6D73A86504","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2020, filed 2020-05-01"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,825,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_414F61974288, https://asof.is/claim/clm_414F61974288, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000031/0000318154-20-000031-index.htm.","url":"https://asof.is/claim/clm_414F61974288","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,825,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_414F61974288","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2020, filed 2020-05-01"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 6,161,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_569470E5C2FB, https://asof.is/claim/clm_569470E5C2FB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000031/0000318154-20-000031-index.htm.","url":"https://asof.is/claim/clm_569470E5C2FB","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,161,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_569470E5C2FB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2020, filed 2020-05-01"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 9,485,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_8CEE5F0631D9, https://asof.is/claim/clm_8CEE5F0631D9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000031/0000318154-20-000031-index.htm.","url":"https://asof.is/claim/clm_8CEE5F0631D9","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"9,485,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8CEE5F0631D9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2020, filed 2020-05-01"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,355,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_BEF30CEEC59D, https://asof.is/claim/clm_BEF30CEEC59D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000031/0000318154-20-000031-index.htm.","url":"https://asof.is/claim/clm_BEF30CEEC59D","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,355,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BEF30CEEC59D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2020, filed 2020-05-01"}},{"date":"2020-04-27","until":"2020-07-23","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 588,247,399 shares\", as of 2020-04-27 (until 2020-07-23). Claim clm_D739E45E5467, https://asof.is/claim/clm_D739E45E5467, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000031/0000318154-20-000031-index.htm.","url":"https://asof.is/claim/clm_D739E45E5467","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"588,247,399 shares","status":"superseded","assertable":true,"id":"clm_D739E45E5467","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2020, filed 2020-05-01"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 9,145,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_43AFE12FE2B4, https://asof.is/claim/clm_43AFE12FE2B4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000048/0000318154-20-000048-index.htm.","url":"https://asof.is/claim/clm_43AFE12FE2B4","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"9,145,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_43AFE12FE2B4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2020, filed 2020-07-29"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 65,011,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_62DDE4D8FE1C, https://asof.is/claim/clm_62DDE4D8FE1C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000048/0000318154-20-000048-index.htm.","url":"https://asof.is/claim/clm_62DDE4D8FE1C","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"65,011,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_62DDE4D8FE1C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2020, filed 2020-07-29"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,803,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_99BF980BB9EA, https://asof.is/claim/clm_99BF980BB9EA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000048/0000318154-20-000048-index.htm.","url":"https://asof.is/claim/clm_99BF980BB9EA","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,803,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_99BF980BB9EA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2020, filed 2020-07-29"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 10,659,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_A29CDA8096D2, https://asof.is/claim/clm_A29CDA8096D2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000048/0000318154-20-000048-index.htm.","url":"https://asof.is/claim/clm_A29CDA8096D2","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"10,659,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A29CDA8096D2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2020, filed 2020-07-29"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 6,206,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_CCB0903B5673, https://asof.is/claim/clm_CCB0903B5673, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000048/0000318154-20-000048-index.htm.","url":"https://asof.is/claim/clm_CCB0903B5673","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,206,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CCB0903B5673","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2020, filed 2020-07-29"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,323,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_CCCD3C3FB13D, https://asof.is/claim/clm_CCCD3C3FB13D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000048/0000318154-20-000048-index.htm.","url":"https://asof.is/claim/clm_CCCD3C3FB13D","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,323,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CCCD3C3FB13D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2020, filed 2020-07-29"}},{"date":"2020-07-23","until":"2020-10-23","published":"2020-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 585,693,775 shares\", as of 2020-07-23 (until 2020-10-23). Claim clm_1A0716269BBF, https://asof.is/claim/clm_1A0716269BBF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000048/0000318154-20-000048-index.htm.","url":"https://asof.is/claim/clm_1A0716269BBF","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"585,693,775 shares","status":"superseded","assertable":true,"id":"clm_1A0716269BBF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2020, filed 2020-07-29"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,453,000,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_03D15401052C, https://asof.is/claim/clm_03D15401052C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000060/0000318154-20-000060-index.htm.","url":"https://asof.is/claim/clm_03D15401052C","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,453,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_03D15401052C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2020, filed 2020-10-29"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 2,021,000,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_733FEFB5E7FA, https://asof.is/claim/clm_733FEFB5E7FA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000060/0000318154-20-000060-index.htm.","url":"https://asof.is/claim/clm_733FEFB5E7FA","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"2,021,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_733FEFB5E7FA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2020, filed 2020-10-29"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 6,423,000,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_A9C5A1ACE96F, https://asof.is/claim/clm_A9C5A1ACE96F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000060/0000318154-20-000060-index.htm.","url":"https://asof.is/claim/clm_A9C5A1ACE96F","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,423,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A9C5A1ACE96F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2020, filed 2020-10-29"}},{"date":"2020-09-30","until":"2020-12-31","published":"2020-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 64,637,000,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_D6F0A4676DE8, https://asof.is/claim/clm_D6F0A4676DE8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000060/0000318154-20-000060-index.htm.","url":"https://asof.is/claim/clm_D6F0A4676DE8","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"64,637,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D6F0A4676DE8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2020, filed 2020-10-29"}},{"date":"2020-09-30","until":"2020-12-31","published":"2020-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 10,959,000,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_F743BC59372A, https://asof.is/claim/clm_F743BC59372A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000060/0000318154-20-000060-index.htm.","url":"https://asof.is/claim/clm_F743BC59372A","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"10,959,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F743BC59372A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2020, filed 2020-10-29"}},{"date":"2020-09-30","until":"2020-12-31","published":"2020-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 9,087,000,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_FB8BB664393E, https://asof.is/claim/clm_FB8BB664393E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000060/0000318154-20-000060-index.htm.","url":"https://asof.is/claim/clm_FB8BB664393E","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"9,087,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FB8BB664393E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2020, filed 2020-10-29"}},{"date":"2020-10-23","until":"2021-02-03","published":"2020-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 582,168,612 shares\", as of 2020-10-23 (until 2021-02-03). Claim clm_0909C448022C, https://asof.is/claim/clm_0909C448022C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815420000060/0000318154-20-000060-index.htm.","url":"https://asof.is/claim/clm_0909C448022C","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"582,168,612 shares","status":"superseded","assertable":true,"id":"clm_0909C448022C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2020, filed 2020-10-29"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 25,424,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_2B6D201D77C0, https://asof.is/claim/clm_2B6D201D77C0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000010/0000318154-21-000010-index.htm.","url":"https://asof.is/claim/clm_2B6D201D77C0","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"25,424,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2B6D201D77C0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2020, filed 2021-02-09"}},{"date":"2020-12-31","until":"2021-03-31","published":"2021-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 6,266,000,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_3796FE9524B2, https://asof.is/claim/clm_3796FE9524B2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000010/0000318154-21-000010-index.htm.","url":"https://asof.is/claim/clm_3796FE9524B2","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"6,266,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3796FE9524B2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2020, filed 2021-02-09"}},{"date":"2020-12-31","until":"2021-03-31","published":"2021-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 9,409,000,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_6140719BE0F5, https://asof.is/claim/clm_6140719BE0F5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000010/0000318154-21-000010-index.htm.","url":"https://asof.is/claim/clm_6140719BE0F5","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"9,409,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6140719BE0F5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2020, filed 2021-02-09"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 7,264,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_673D61CD1F43, https://asof.is/claim/clm_673D61CD1F43, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000010/0000318154-21-000010-index.htm.","url":"https://asof.is/claim/clm_673D61CD1F43","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"7,264,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_673D61CD1F43","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2020, filed 2021-02-09"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 9,139,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_926C65AE4F09, https://asof.is/claim/clm_926C65AE4F09, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000010/0000318154-21-000010-index.htm.","url":"https://asof.is/claim/clm_926C65AE4F09","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"9,139,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_926C65AE4F09","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2020, filed 2021-02-09"}},{"date":"2020-12-31","until":"2021-03-31","published":"2021-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 62,948,000,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_EA5FD7A5E873, https://asof.is/claim/clm_EA5FD7A5E873, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000010/0000318154-21-000010-index.htm.","url":"https://asof.is/claim/clm_EA5FD7A5E873","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"62,948,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EA5FD7A5E873","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2020, filed 2021-02-09"}},{"date":"2021-02-03","until":"2021-04-22","published":"2021-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 577,566,383 shares\", as of 2021-02-03 (until 2021-04-22). Claim clm_3ED771217180, https://asof.is/claim/clm_3ED771217180, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000010/0000318154-21-000010-index.htm.","url":"https://asof.is/claim/clm_3ED771217180","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"577,566,383 shares","status":"superseded","assertable":true,"id":"clm_3ED771217180","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2020, filed 2021-02-09"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 9,334,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_38D0C83AFC61, https://asof.is/claim/clm_38D0C83AFC61, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000019/0000318154-21-000019-index.htm.","url":"https://asof.is/claim/clm_38D0C83AFC61","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"9,334,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_38D0C83AFC61","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2021, filed 2021-04-28"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,129,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_687CDFCB7970, https://asof.is/claim/clm_687CDFCB7970, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000019/0000318154-21-000019-index.htm.","url":"https://asof.is/claim/clm_687CDFCB7970","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,129,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_687CDFCB7970","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2021, filed 2021-04-28"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,646,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_6B1B858C967C, https://asof.is/claim/clm_6B1B858C967C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000019/0000318154-21-000019-index.htm.","url":"https://asof.is/claim/clm_6B1B858C967C","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,646,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6B1B858C967C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2021, filed 2021-04-28"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 6,112,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_8D9D5DB7A5DE, https://asof.is/claim/clm_8D9D5DB7A5DE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000019/0000318154-21-000019-index.htm.","url":"https://asof.is/claim/clm_8D9D5DB7A5DE","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"6,112,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8D9D5DB7A5DE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2021, filed 2021-04-28"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 5,901,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_9E8DA72630EB, https://asof.is/claim/clm_9E8DA72630EB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000019/0000318154-21-000019-index.htm.","url":"https://asof.is/claim/clm_9E8DA72630EB","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,901,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9E8DA72630EB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2021, filed 2021-04-28"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 62,539,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_9F85DA6C69DF, https://asof.is/claim/clm_9F85DA6C69DF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000019/0000318154-21-000019-index.htm.","url":"https://asof.is/claim/clm_9F85DA6C69DF","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"62,539,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9F85DA6C69DF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2021, filed 2021-04-28"}},{"date":"2021-04-22","until":"2021-07-29","published":"2021-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 574,553,986 shares\", as of 2021-04-22 (until 2021-07-29). Claim clm_45F0A6B25113, https://asof.is/claim/clm_45F0A6B25113, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000019/0000318154-21-000019-index.htm.","url":"https://asof.is/claim/clm_45F0A6B25113","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"574,553,986 shares","status":"superseded","assertable":true,"id":"clm_45F0A6B25113","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2021, filed 2021-04-28"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 8,247,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_3DEAF95EF6B0, https://asof.is/claim/clm_3DEAF95EF6B0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000034/0000318154-21-000034-index.htm.","url":"https://asof.is/claim/clm_3DEAF95EF6B0","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"8,247,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3DEAF95EF6B0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2021, filed 2021-08-04"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 59,773,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_627ADC7F9C5A, https://asof.is/claim/clm_627ADC7F9C5A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000034/0000318154-21-000034-index.htm.","url":"https://asof.is/claim/clm_627ADC7F9C5A","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"59,773,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_627ADC7F9C5A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2021, filed 2021-08-04"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 6,526,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_C2407B4C4D35, https://asof.is/claim/clm_C2407B4C4D35, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000034/0000318154-21-000034-index.htm.","url":"https://asof.is/claim/clm_C2407B4C4D35","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,526,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C2407B4C4D35","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2021, filed 2021-08-04"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 464,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_C8266FA25464, https://asof.is/claim/clm_C8266FA25464, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000034/0000318154-21-000034-index.htm.","url":"https://asof.is/claim/clm_C8266FA25464","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"464,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C8266FA25464","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2021, filed 2021-08-04"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 828,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_CDC5FFCBE990, https://asof.is/claim/clm_CDC5FFCBE990, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000034/0000318154-21-000034-index.htm.","url":"https://asof.is/claim/clm_CDC5FFCBE990","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"828,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CDC5FFCBE990","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2021, filed 2021-08-04"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 6,630,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_EE459468FEEE, https://asof.is/claim/clm_EE459468FEEE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000034/0000318154-21-000034-index.htm.","url":"https://asof.is/claim/clm_EE459468FEEE","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"6,630,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EE459468FEEE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2021, filed 2021-08-04"}},{"date":"2021-07-29","until":"2021-10-28","published":"2021-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 567,852,353 shares\", as of 2021-07-29 (until 2021-10-28). Claim clm_096FA3E02484, https://asof.is/claim/clm_096FA3E02484, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000034/0000318154-21-000034-index.htm.","url":"https://asof.is/claim/clm_096FA3E02484","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"567,852,353 shares","status":"superseded","assertable":true,"id":"clm_096FA3E02484","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2021, filed 2021-08-04"}},{"date":"2021-09-30","until":"2021-12-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 8,217,000,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_6DC2B1698886, https://asof.is/claim/clm_6DC2B1698886, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000045/0000318154-21-000045-index.htm.","url":"https://asof.is/claim/clm_6DC2B1698886","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"8,217,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6DC2B1698886","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2021, filed 2021-11-03"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 6,706,000,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_77995E036FCF, https://asof.is/claim/clm_77995E036FCF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000045/0000318154-21-000045-index.htm.","url":"https://asof.is/claim/clm_77995E036FCF","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,706,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_77995E036FCF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2021, filed 2021-11-03"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,884,000,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_79D0F6379AE0, https://asof.is/claim/clm_79D0F6379AE0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000045/0000318154-21-000045-index.htm.","url":"https://asof.is/claim/clm_79D0F6379AE0","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,884,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_79D0F6379AE0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2021, filed 2021-11-03"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,378,000,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_971916A525E3, https://asof.is/claim/clm_971916A525E3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000045/0000318154-21-000045-index.htm.","url":"https://asof.is/claim/clm_971916A525E3","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,378,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_971916A525E3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2021, filed 2021-11-03"}},{"date":"2021-09-30","until":"2021-12-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 11,969,000,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_A5791D18E55A, https://asof.is/claim/clm_A5791D18E55A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000045/0000318154-21-000045-index.htm.","url":"https://asof.is/claim/clm_A5791D18E55A","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"11,969,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A5791D18E55A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2021, filed 2021-11-03"}},{"date":"2021-09-30","until":"2021-12-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 64,993,000,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_BD51A9765CB0, https://asof.is/claim/clm_BD51A9765CB0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000045/0000318154-21-000045-index.htm.","url":"https://asof.is/claim/clm_BD51A9765CB0","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"64,993,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BD51A9765CB0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2021, filed 2021-11-03"}},{"date":"2021-10-28","until":"2022-02-11","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 563,265,902 shares\", as of 2021-10-28 (until 2022-02-11). Claim clm_06A251E59EBC, https://asof.is/claim/clm_06A251E59EBC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815421000045/0000318154-21-000045-index.htm.","url":"https://asof.is/claim/clm_06A251E59EBC","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"563,265,902 shares","status":"superseded","assertable":true,"id":"clm_06A251E59EBC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2021, filed 2021-11-03"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 7,639,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_018B07550FF4, https://asof.is/claim/clm_018B07550FF4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/0000318154-22-000010-index.htm.","url":"https://asof.is/claim/clm_018B07550FF4","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"7,639,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_018B07550FF4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2021, filed 2022-02-16"}},{"date":"2021-12-31","until":"2022-03-31","published":"2022-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 61,165,000,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_43D551B4FBB5, https://asof.is/claim/clm_43D551B4FBB5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/0000318154-22-000010-index.htm.","url":"https://asof.is/claim/clm_43D551B4FBB5","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"61,165,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_43D551B4FBB5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2021, filed 2022-02-16"}},{"date":"2021-12-31","until":"2022-03-31","published":"2022-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 7,989,000,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_65015952E899, https://asof.is/claim/clm_65015952E899, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/0000318154-22-000010-index.htm.","url":"https://asof.is/claim/clm_65015952E899","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"7,989,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_65015952E899","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2021, filed 2022-02-16"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 25,979,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_77883252E88F, https://asof.is/claim/clm_77883252E88F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/0000318154-22-000010-index.htm.","url":"https://asof.is/claim/clm_77883252E88F","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"25,979,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_77883252E88F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2021, filed 2022-02-16"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 5,893,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_BF2E5D6BD634, https://asof.is/claim/clm_BF2E5D6BD634, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/0000318154-22-000010-index.htm.","url":"https://asof.is/claim/clm_BF2E5D6BD634","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"5,893,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BF2E5D6BD634","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2021, filed 2022-02-16"}},{"date":"2021-12-31","until":"2022-03-31","published":"2022-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 6,700,000,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_BF8A71350904, https://asof.is/claim/clm_BF8A71350904, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/0000318154-22-000010-index.htm.","url":"https://asof.is/claim/clm_BF8A71350904","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"6,700,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BF8A71350904","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2021, filed 2022-02-16"}},{"date":"2022-02-11","until":"2022-04-22","published":"2022-02-16","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 557,029,370 shares\", as of 2022-02-11 (until 2022-04-22). Claim clm_BA677DC55A32, https://asof.is/claim/clm_BA677DC55A32, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000010/0000318154-22-000010-index.htm.","url":"https://asof.is/claim/clm_BA677DC55A32","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"557,029,370 shares","status":"superseded","assertable":true,"id":"clm_BA677DC55A32","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2021, filed 2022-02-16"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,476,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_14453E457A66, https://asof.is/claim/clm_14453E457A66, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000021/0000318154-22-000021-index.htm.","url":"https://asof.is/claim/clm_14453E457A66","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,476,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_14453E457A66","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2022, filed 2022-04-28"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 59,196,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_4956EE655EA9, https://asof.is/claim/clm_4956EE655EA9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000021/0000318154-22-000021-index.htm.","url":"https://asof.is/claim/clm_4956EE655EA9","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"59,196,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4956EE655EA9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2022, filed 2022-04-28"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,500,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_5EAB20C5AA2A, https://asof.is/claim/clm_5EAB20C5AA2A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000021/0000318154-22-000021-index.htm.","url":"https://asof.is/claim/clm_5EAB20C5AA2A","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,500,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5EAB20C5AA2A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2022, filed 2022-04-28"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 916,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_68A37D10302E, https://asof.is/claim/clm_68A37D10302E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000021/0000318154-22-000021-index.htm.","url":"https://asof.is/claim/clm_68A37D10302E","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"916,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_68A37D10302E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2022, filed 2022-04-28"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 6,238,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_7ED75B6E7D04, https://asof.is/claim/clm_7ED75B6E7D04, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000021/0000318154-22-000021-index.htm.","url":"https://asof.is/claim/clm_7ED75B6E7D04","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,238,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7ED75B6E7D04","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2022, filed 2022-04-28"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 6,528,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_F90753F8299C, https://asof.is/claim/clm_F90753F8299C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000021/0000318154-22-000021-index.htm.","url":"https://asof.is/claim/clm_F90753F8299C","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"6,528,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F90753F8299C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2022, filed 2022-04-28"}},{"date":"2022-04-22","until":"2022-08-01","published":"2022-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 534,199,933 shares\", as of 2022-04-22 (until 2022-08-01). Claim clm_F932B282715C, https://asof.is/claim/clm_F932B282715C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000021/0000318154-22-000021-index.htm.","url":"https://asof.is/claim/clm_F932B282715C","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"534,199,933 shares","status":"superseded","assertable":true,"id":"clm_F932B282715C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2022, filed 2022-04-28"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 5,203,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_2C58ADDE4DED, https://asof.is/claim/clm_2C58ADDE4DED, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000041/0000318154-22-000041-index.htm.","url":"https://asof.is/claim/clm_2C58ADDE4DED","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"5,203,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2C58ADDE4DED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2022, filed 2022-08-05"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 2,419,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_4BB765E7F1FC, https://asof.is/claim/clm_4BB765E7F1FC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000041/0000318154-22-000041-index.htm.","url":"https://asof.is/claim/clm_4BB765E7F1FC","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"2,419,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4BB765E7F1FC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2022, filed 2022-08-05"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,317,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_7BC494395A3F, https://asof.is/claim/clm_7BC494395A3F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000041/0000318154-22-000041-index.htm.","url":"https://asof.is/claim/clm_7BC494395A3F","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,317,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7BC494395A3F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2022, filed 2022-08-05"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 6,594,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_8C035E8371E9, https://asof.is/claim/clm_8C035E8371E9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000041/0000318154-22-000041-index.htm.","url":"https://asof.is/claim/clm_8C035E8371E9","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,594,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8C035E8371E9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2022, filed 2022-08-05"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 59,294,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_D091B9D69D1A, https://asof.is/claim/clm_D091B9D69D1A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000041/0000318154-22-000041-index.htm.","url":"https://asof.is/claim/clm_D091B9D69D1A","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"59,294,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D091B9D69D1A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2022, filed 2022-08-05"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,176,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_E5A8056A8B32, https://asof.is/claim/clm_E5A8056A8B32, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000041/0000318154-22-000041-index.htm.","url":"https://asof.is/claim/clm_E5A8056A8B32","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,176,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E5A8056A8B32","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2022, filed 2022-08-05"}},{"date":"2022-08-01","until":"2022-10-31","published":"2022-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 534,930,850 shares\", as of 2022-08-01 (until 2022-10-31). Claim clm_178FD19F2105, https://asof.is/claim/clm_178FD19F2105, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000041/0000318154-22-000041-index.htm.","url":"https://asof.is/claim/clm_178FD19F2105","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"534,930,850 shares","status":"superseded","assertable":true,"id":"clm_178FD19F2105","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2022, filed 2022-08-05"}},{"date":"2022-09-30","until":"2022-12-31","published":"2022-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 63,700,000,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_2130B296B9EF, https://asof.is/claim/clm_2130B296B9EF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000055/0000318154-22-000055-index.htm.","url":"https://asof.is/claim/clm_2130B296B9EF","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"63,700,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2130B296B9EF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2022, filed 2022-11-04"}},{"date":"2022-09-30","until":"2022-12-31","published":"2022-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 3,653,000,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_2983532AC508, https://asof.is/claim/clm_2983532AC508, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000055/0000318154-22-000055-index.htm.","url":"https://asof.is/claim/clm_2983532AC508","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"3,653,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2983532AC508","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2022, filed 2022-11-04"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 2,143,000,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_35CDE21699AB, https://asof.is/claim/clm_35CDE21699AB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000055/0000318154-22-000055-index.htm.","url":"https://asof.is/claim/clm_35CDE21699AB","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"2,143,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_35CDE21699AB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2022, filed 2022-11-04"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 6,652,000,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_5A9AC839EF5A, https://asof.is/claim/clm_5A9AC839EF5A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000055/0000318154-22-000055-index.htm.","url":"https://asof.is/claim/clm_5A9AC839EF5A","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,652,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5A9AC839EF5A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2022, filed 2022-11-04"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,660,000,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_78C2CEAEC57D, https://asof.is/claim/clm_78C2CEAEC57D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000055/0000318154-22-000055-index.htm.","url":"https://asof.is/claim/clm_78C2CEAEC57D","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,660,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_78C2CEAEC57D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2022, filed 2022-11-04"}},{"date":"2022-09-30","until":"2022-12-31","published":"2022-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 9,502,000,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_BDE07F9B7128, https://asof.is/claim/clm_BDE07F9B7128, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000055/0000318154-22-000055-index.htm.","url":"https://asof.is/claim/clm_BDE07F9B7128","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"9,502,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BDE07F9B7128","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2022, filed 2022-11-04"}},{"date":"2022-10-31","until":"2023-02-06","published":"2022-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 533,579,206 shares\", as of 2022-10-31 (until 2023-02-06). Claim clm_C279B018E45E, https://asof.is/claim/clm_C279B018E45E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815422000055/0000318154-22-000055-index.htm.","url":"https://asof.is/claim/clm_C279B018E45E","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"533,579,206 shares","status":"superseded","assertable":true,"id":"clm_C279B018E45E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2022, filed 2022-11-04"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 9,566,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_0207ECA7A000, https://asof.is/claim/clm_0207ECA7A000, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000017/0000318154-23-000017-index.htm.","url":"https://asof.is/claim/clm_0207ECA7A000","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"9,566,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0207ECA7A000","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2022, filed 2023-02-09"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 26,323,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_142A6C7A0E55, https://asof.is/claim/clm_142A6C7A0E55, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000017/0000318154-23-000017-index.htm.","url":"https://asof.is/claim/clm_142A6C7A0E55","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"26,323,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_142A6C7A0E55","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2022, filed 2023-02-09"}},{"date":"2022-12-31","until":"2023-03-31","published":"2023-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 65,121,000,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_3E5FFAF79DFE, https://asof.is/claim/clm_3E5FFAF79DFE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000017/0000318154-23-000017-index.htm.","url":"https://asof.is/claim/clm_3E5FFAF79DFE","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"65,121,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3E5FFAF79DFE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2022, filed 2023-02-09"}},{"date":"2022-12-31","until":"2023-03-31","published":"2023-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 3,661,000,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_4BA44A742FE5, https://asof.is/claim/clm_4BA44A742FE5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000017/0000318154-23-000017-index.htm.","url":"https://asof.is/claim/clm_4BA44A742FE5","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"3,661,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4BA44A742FE5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2022, filed 2023-02-09"}},{"date":"2022-12-31","until":"2023-03-31","published":"2023-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 7,629,000,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_9441264854A2, https://asof.is/claim/clm_9441264854A2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000017/0000318154-23-000017-index.htm.","url":"https://asof.is/claim/clm_9441264854A2","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"7,629,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9441264854A2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2022, filed 2023-02-09"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 6,552,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_C644E157DE79, https://asof.is/claim/clm_C644E157DE79, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000017/0000318154-23-000017-index.htm.","url":"https://asof.is/claim/clm_C644E157DE79","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"6,552,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C644E157DE79","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2022, filed 2023-02-09"}},{"date":"2023-02-06","until":"2023-04-24","published":"2023-02-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 533,976,238 shares\", as of 2023-02-06 (until 2023-04-24). Claim clm_7EB6F1E516E7, https://asof.is/claim/clm_7EB6F1E516E7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000017/0000318154-23-000017-index.htm.","url":"https://asof.is/claim/clm_7EB6F1E516E7","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"533,976,238 shares","status":"superseded","assertable":true,"id":"clm_7EB6F1E516E7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2022, filed 2023-02-09"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 31,560,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_0B4F8228696C, https://asof.is/claim/clm_0B4F8228696C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000029/0000318154-23-000029-index.htm.","url":"https://asof.is/claim/clm_0B4F8228696C","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"31,560,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0B4F8228696C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2023, filed 2023-04-28"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 2,841,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_1A5FC1FEF0D4, https://asof.is/claim/clm_1A5FC1FEF0D4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000029/0000318154-23-000029-index.htm.","url":"https://asof.is/claim/clm_1A5FC1FEF0D4","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"2,841,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1A5FC1FEF0D4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2023, filed 2023-04-28"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 6,105,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_481E925C620E, https://asof.is/claim/clm_481E925C620E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000029/0000318154-23-000029-index.htm.","url":"https://asof.is/claim/clm_481E925C620E","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,105,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_481E925C620E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2023, filed 2023-04-28"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,921,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_87A3CD3A03BE, https://asof.is/claim/clm_87A3CD3A03BE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000029/0000318154-23-000029-index.htm.","url":"https://asof.is/claim/clm_87A3CD3A03BE","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,921,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_87A3CD3A03BE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2023, filed 2023-04-28"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 5,348,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_DD0F42269A48, https://asof.is/claim/clm_DD0F42269A48, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000029/0000318154-23-000029-index.htm.","url":"https://asof.is/claim/clm_DD0F42269A48","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"5,348,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DD0F42269A48","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2023, filed 2023-04-28"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 88,720,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_F5CDB4E2EE9B, https://asof.is/claim/clm_F5CDB4E2EE9B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000029/0000318154-23-000029-index.htm.","url":"https://asof.is/claim/clm_F5CDB4E2EE9B","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"88,720,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F5CDB4E2EE9B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2023, filed 2023-04-28"}},{"date":"2023-04-24","until":"2023-07-31","published":"2023-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 534,326,594 shares\", as of 2023-04-24 (until 2023-07-31). Claim clm_69A1D6DBF618, https://asof.is/claim/clm_69A1D6DBF618, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000029/0000318154-23-000029-index.htm.","url":"https://asof.is/claim/clm_69A1D6DBF618","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"534,326,594 shares","status":"superseded","assertable":true,"id":"clm_69A1D6DBF618","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2023, filed 2023-04-28"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,379,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_2B91AA0524E8, https://asof.is/claim/clm_2B91AA0524E8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000053/0000318154-23-000053-index.htm.","url":"https://asof.is/claim/clm_2B91AA0524E8","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,379,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2B91AA0524E8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2023, filed 2023-08-04"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 6,781,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_3DDAC5296A48, https://asof.is/claim/clm_3DDAC5296A48, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000053/0000318154-23-000053-index.htm.","url":"https://asof.is/claim/clm_3DDAC5296A48","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"6,781,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3DDAC5296A48","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2023, filed 2023-08-04"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,684,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_5A3FD4672B1E, https://asof.is/claim/clm_5A3FD4672B1E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000053/0000318154-23-000053-index.htm.","url":"https://asof.is/claim/clm_5A3FD4672B1E","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,684,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5A3FD4672B1E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2023, filed 2023-08-04"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 6,986,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_92E3CC76739F, https://asof.is/claim/clm_92E3CC76739F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000053/0000318154-23-000053-index.htm.","url":"https://asof.is/claim/clm_92E3CC76739F","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,986,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_92E3CC76739F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2023, filed 2023-08-04"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 34,248,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_ADA1FFC461F7, https://asof.is/claim/clm_ADA1FFC461F7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000053/0000318154-23-000053-index.htm.","url":"https://asof.is/claim/clm_ADA1FFC461F7","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"34,248,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ADA1FFC461F7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2023, filed 2023-08-04"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 90,269,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_E898DB814445, https://asof.is/claim/clm_E898DB814445, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000053/0000318154-23-000053-index.htm.","url":"https://asof.is/claim/clm_E898DB814445","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"90,269,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E898DB814445","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2023, filed 2023-08-04"}},{"date":"2023-07-31","until":"2023-10-26","published":"2023-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 534,901,181 shares\", as of 2023-07-31 (until 2023-10-26). Claim clm_613418445F18, https://asof.is/claim/clm_613418445F18, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000053/0000318154-23-000053-index.htm.","url":"https://asof.is/claim/clm_613418445F18","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"534,901,181 shares","status":"superseded","assertable":true,"id":"clm_613418445F18","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2023, filed 2023-08-04"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,730,000,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_12D32BFD074A, https://asof.is/claim/clm_12D32BFD074A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000064/0000318154-23-000064-index.htm.","url":"https://asof.is/claim/clm_12D32BFD074A","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,730,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_12D32BFD074A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2023, filed 2023-10-31"}},{"date":"2023-09-30","until":"2023-12-31","published":"2023-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 34,741,000,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_49C1DCF00977, https://asof.is/claim/clm_49C1DCF00977, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000064/0000318154-23-000064-index.htm.","url":"https://asof.is/claim/clm_49C1DCF00977","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"34,741,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_49C1DCF00977","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2023, filed 2023-10-31"}},{"date":"2023-09-30","until":"2023-12-31","published":"2023-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 90,534,000,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_8D2BB66829A3, https://asof.is/claim/clm_8D2BB66829A3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000064/0000318154-23-000064-index.htm.","url":"https://asof.is/claim/clm_8D2BB66829A3","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"90,534,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8D2BB66829A3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2023, filed 2023-10-31"}},{"date":"2023-09-30","until":"2023-12-31","published":"2023-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 7,656,000,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_C48050D45C2E, https://asof.is/claim/clm_C48050D45C2E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000064/0000318154-23-000064-index.htm.","url":"https://asof.is/claim/clm_C48050D45C2E","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"7,656,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C48050D45C2E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2023, filed 2023-10-31"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 6,903,000,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_DC8081A3AB65, https://asof.is/claim/clm_DC8081A3AB65, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000064/0000318154-23-000064-index.htm.","url":"https://asof.is/claim/clm_DC8081A3AB65","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,903,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DC8081A3AB65","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2023, filed 2023-10-31"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,021,000,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_EA063E4EB60A, https://asof.is/claim/clm_EA063E4EB60A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000064/0000318154-23-000064-index.htm.","url":"https://asof.is/claim/clm_EA063E4EB60A","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,021,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EA063E4EB60A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2023, filed 2023-10-31"}},{"date":"2023-10-26","until":"2024-02-09","published":"2023-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 535,178,027 shares\", as of 2023-10-26 (until 2024-02-09). Claim clm_70B9E417B378, https://asof.is/claim/clm_70B9E417B378, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815423000064/0000318154-23-000064-index.htm.","url":"https://asof.is/claim/clm_70B9E417B378","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"535,178,027 shares","status":"superseded","assertable":true,"id":"clm_70B9E417B378","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2023, filed 2023-10-31"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 97,154,000,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_28FA2561E047, https://asof.is/claim/clm_28FA2561E047, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/0000318154-24-000011-index.htm.","url":"https://asof.is/claim/clm_28FA2561E047","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"97,154,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_28FA2561E047","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2023, filed 2024-02-14"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 6,717,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_566AA4B9BFA3, https://asof.is/claim/clm_566AA4B9BFA3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/0000318154-24-000011-index.htm.","url":"https://asof.is/claim/clm_566AA4B9BFA3","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"6,717,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_566AA4B9BFA3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2023, filed 2024-02-14"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 10,944,000,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_71DDBB020158, https://asof.is/claim/clm_71DDBB020158, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/0000318154-24-000011-index.htm.","url":"https://asof.is/claim/clm_71DDBB020158","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"10,944,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_71DDBB020158","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2023, filed 2024-02-14"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 28,190,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_C49E0455CA9B, https://asof.is/claim/clm_C49E0455CA9B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/0000318154-24-000011-index.htm.","url":"https://asof.is/claim/clm_C49E0455CA9B","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"28,190,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C49E0455CA9B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2023, filed 2024-02-14"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 7,897,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_D213C7365716, https://asof.is/claim/clm_D213C7365716, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/0000318154-24-000011-index.htm.","url":"https://asof.is/claim/clm_D213C7365716","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"7,897,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D213C7365716","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2023, filed 2024-02-14"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 6,232,000,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_E5BB4CC8EC5C, https://asof.is/claim/clm_E5BB4CC8EC5C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/0000318154-24-000011-index.htm.","url":"https://asof.is/claim/clm_E5BB4CC8EC5C","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"6,232,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E5BB4CC8EC5C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2023, filed 2024-02-14"}},{"date":"2024-02-09","until":"2024-04-29","published":"2024-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 535,918,901 shares\", as of 2024-02-09 (until 2024-04-29). Claim clm_5D00EFAD6C71, https://asof.is/claim/clm_5D00EFAD6C71, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000011/0000318154-24-000011-index.htm.","url":"https://asof.is/claim/clm_5D00EFAD6C71","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"535,918,901 shares","status":"superseded","assertable":true,"id":"clm_5D00EFAD6C71","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2023, filed 2024-02-14"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 7,447,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_458A0C01DCF8, https://asof.is/claim/clm_458A0C01DCF8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000020/0000318154-24-000020-index.htm.","url":"https://asof.is/claim/clm_458A0C01DCF8","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"7,447,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_458A0C01DCF8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2024, filed 2024-05-03"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 92,980,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_50E0EA85B3CF, https://asof.is/claim/clm_50E0EA85B3CF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000020/0000318154-24-000020-index.htm.","url":"https://asof.is/claim/clm_50E0EA85B3CF","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"92,980,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_50E0EA85B3CF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2024, filed 2024-05-03"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 991,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_603D27640F44, https://asof.is/claim/clm_603D27640F44, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000020/0000318154-24-000020-index.htm.","url":"https://asof.is/claim/clm_603D27640F44","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"991,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_603D27640F44","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2024, filed 2024-05-03"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 5,022,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_713550ADBC39, https://asof.is/claim/clm_713550ADBC39, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000020/0000318154-24-000020-index.htm.","url":"https://asof.is/claim/clm_713550ADBC39","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"5,022,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_713550ADBC39","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2024, filed 2024-05-03"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 9,708,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_85A3377148F1, https://asof.is/claim/clm_85A3377148F1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000020/0000318154-24-000020-index.htm.","url":"https://asof.is/claim/clm_85A3377148F1","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"9,708,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_85A3377148F1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2024, filed 2024-05-03"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: -113,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_E9B14F8E9889, https://asof.is/claim/clm_E9B14F8E9889, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000020/0000318154-24-000020-index.htm.","url":"https://asof.is/claim/clm_E9B14F8E9889","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"-113,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E9B14F8E9889","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2024, filed 2024-05-03"}},{"date":"2024-04-29","until":"2024-08-01","published":"2024-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 536,434,692 shares\", as of 2024-04-29 (until 2024-08-01). Claim clm_7FEA7977C094, https://asof.is/claim/clm_7FEA7977C094, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000020/0000318154-24-000020-index.htm.","url":"https://asof.is/claim/clm_7FEA7977C094","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"536,434,692 shares","status":"superseded","assertable":true,"id":"clm_7FEA7977C094","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2024, filed 2024-05-03"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 9,301,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_7A6976D86AF0, https://asof.is/claim/clm_7A6976D86AF0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000035/0000318154-24-000035-index.htm.","url":"https://asof.is/claim/clm_7A6976D86AF0","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"9,301,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7A6976D86AF0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2024, filed 2024-08-07"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 746,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_7FB87156E0B7, https://asof.is/claim/clm_7FB87156E0B7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000035/0000318154-24-000035-index.htm.","url":"https://asof.is/claim/clm_7FB87156E0B7","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"746,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7FB87156E0B7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2024, filed 2024-08-07"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 5,925,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_AC23A926EFAF, https://asof.is/claim/clm_AC23A926EFAF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000035/0000318154-24-000035-index.htm.","url":"https://asof.is/claim/clm_AC23A926EFAF","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"5,925,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AC23A926EFAF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2024, filed 2024-08-07"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 8,388,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_CE8800B79AA0, https://asof.is/claim/clm_CE8800B79AA0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000035/0000318154-24-000035-index.htm.","url":"https://asof.is/claim/clm_CE8800B79AA0","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"8,388,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CE8800B79AA0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2024, filed 2024-08-07"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,909,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_DD998C1C3CBA, https://asof.is/claim/clm_DD998C1C3CBA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000035/0000318154-24-000035-index.htm.","url":"https://asof.is/claim/clm_DD998C1C3CBA","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,909,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DD998C1C3CBA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2024, filed 2024-08-07"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 90,907,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_FB713317C6E9, https://asof.is/claim/clm_FB713317C6E9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000035/0000318154-24-000035-index.htm.","url":"https://asof.is/claim/clm_FB713317C6E9","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"90,907,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FB713317C6E9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2024, filed 2024-08-07"}},{"date":"2024-08-01","until":"2024-10-25","published":"2024-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 537,329,220 shares\", as of 2024-08-01 (until 2024-10-25). Claim clm_17A7DEA15E83, https://asof.is/claim/clm_17A7DEA15E83, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000035/0000318154-24-000035-index.htm.","url":"https://asof.is/claim/clm_17A7DEA15E83","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"537,329,220 shares","status":"superseded","assertable":true,"id":"clm_17A7DEA15E83","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2024, filed 2024-08-07"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 2,830,000,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_3554CF74631E, https://asof.is/claim/clm_3554CF74631E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000044/0000318154-24-000044-index.htm.","url":"https://asof.is/claim/clm_3554CF74631E","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"2,830,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3554CF74631E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2024-12-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 9,011,000,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_635D97E40729, https://asof.is/claim/clm_635D97E40729, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000044/0000318154-24-000044-index.htm.","url":"https://asof.is/claim/clm_635D97E40729","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"9,011,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_635D97E40729","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2024-12-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 7,527,000,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_A4EA1DDC1704, https://asof.is/claim/clm_A4EA1DDC1704, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000044/0000318154-24-000044-index.htm.","url":"https://asof.is/claim/clm_A4EA1DDC1704","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"7,527,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A4EA1DDC1704","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 8,503,000,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_BF9D0F8819AD, https://asof.is/claim/clm_BF9D0F8819AD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000044/0000318154-24-000044-index.htm.","url":"https://asof.is/claim/clm_BF9D0F8819AD","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"8,503,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BF9D0F8819AD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,047,000,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_F7A83EC1A298, https://asof.is/claim/clm_F7A83EC1A298, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000044/0000318154-24-000044-index.htm.","url":"https://asof.is/claim/clm_F7A83EC1A298","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,047,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F7A83EC1A298","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-09-30","until":"2024-12-31","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 90,883,000,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_F88E6D123694, https://asof.is/claim/clm_F88E6D123694, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000044/0000318154-24-000044-index.htm.","url":"https://asof.is/claim/clm_F88E6D123694","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"90,883,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F88E6D123694","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-10-25","until":"2025-02-11","published":"2024-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 537,532,723 shares\", as of 2024-10-25 (until 2025-02-11). Claim clm_8727DF5F4982, https://asof.is/claim/clm_8727DF5F4982, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815424000044/0000318154-24-000044-index.htm.","url":"https://asof.is/claim/clm_8727DF5F4982","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"537,532,723 shares","status":"superseded","assertable":true,"id":"clm_8727DF5F4982","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2024, filed 2024-10-31"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 7,258,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_14D79C128253, https://asof.is/claim/clm_14D79C128253, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm.","url":"https://asof.is/claim/clm_14D79C128253","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"7,258,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_14D79C128253","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-14"}},{"date":"2024-12-31","until":"2025-03-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 5,877,000,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_636768003464, https://asof.is/claim/clm_636768003464, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm.","url":"https://asof.is/claim/clm_636768003464","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"5,877,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_636768003464","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2024, filed 2025-02-14"}},{"date":"2024-12-31","until":"2025-03-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 11,973,000,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_B08ED03B8CC3, https://asof.is/claim/clm_B08ED03B8CC3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm.","url":"https://asof.is/claim/clm_B08ED03B8CC3","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"11,973,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B08ED03B8CC3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2024, filed 2025-02-14"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 4,090,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_ED179BBDEBC9, https://asof.is/claim/clm_ED179BBDEBC9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm.","url":"https://asof.is/claim/clm_ED179BBDEBC9","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"4,090,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ED179BBDEBC9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-14"}},{"date":"2024-12-31","until":"2025-03-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 91,839,000,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_EE06CBFC7149, https://asof.is/claim/clm_EE06CBFC7149, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm.","url":"https://asof.is/claim/clm_EE06CBFC7149","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"91,839,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EE06CBFC7149","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2024, filed 2025-02-14"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 33,424,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_F31DA2CA4F3F, https://asof.is/claim/clm_F31DA2CA4F3F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm.","url":"https://asof.is/claim/clm_F31DA2CA4F3F","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"33,424,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F31DA2CA4F3F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-14"}},{"date":"2025-02-11","until":"2025-04-28","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 537,204,943 shares\", as of 2025-02-11 (until 2025-04-28). Claim clm_3BD301427B1F, https://asof.is/claim/clm_3BD301427B1F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm.","url":"https://asof.is/claim/clm_3BD301427B1F","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"537,204,943 shares","status":"superseded","assertable":true,"id":"clm_3BD301427B1F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2024, filed 2025-02-14"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 8,810,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_089D9CECF18D, https://asof.is/claim/clm_089D9CECF18D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000020/0000318154-25-000020-index.htm.","url":"https://asof.is/claim/clm_089D9CECF18D","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"8,810,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_089D9CECF18D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2025, filed 2025-05-02"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 6,207,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_4988A9F733D5, https://asof.is/claim/clm_4988A9F733D5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000020/0000318154-25-000020-index.htm.","url":"https://asof.is/claim/clm_4988A9F733D5","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"6,207,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4988A9F733D5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2025, filed 2025-05-02"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,730,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_ABB59844DF49, https://asof.is/claim/clm_ABB59844DF49, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000020/0000318154-25-000020-index.htm.","url":"https://asof.is/claim/clm_ABB59844DF49","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,730,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ABB59844DF49","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2025, filed 2025-05-02"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 89,367,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_C9D442A37C8E, https://asof.is/claim/clm_C9D442A37C8E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000020/0000318154-25-000020-index.htm.","url":"https://asof.is/claim/clm_C9D442A37C8E","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"89,367,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C9D442A37C8E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2025, filed 2025-05-02"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 1,178,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_DD5E7F4FA2BB, https://asof.is/claim/clm_DD5E7F4FA2BB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000020/0000318154-25-000020-index.htm.","url":"https://asof.is/claim/clm_DD5E7F4FA2BB","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"1,178,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DD5E7F4FA2BB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2025, filed 2025-05-02"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 8,149,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_FD554405E740, https://asof.is/claim/clm_FD554405E740, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000020/0000318154-25-000020-index.htm.","url":"https://asof.is/claim/clm_FD554405E740","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"8,149,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FD554405E740","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2025, filed 2025-05-02"}},{"date":"2025-04-28","until":"2025-07-31","published":"2025-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 537,706,118 shares\", as of 2025-04-28 (until 2025-07-31). Claim clm_0715D8B97E5E, https://asof.is/claim/clm_0715D8B97E5E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000020/0000318154-25-000020-index.htm.","url":"https://asof.is/claim/clm_0715D8B97E5E","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"537,706,118 shares","status":"superseded","assertable":true,"id":"clm_0715D8B97E5E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2025, filed 2025-05-02"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 7,428,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_3C68D4BBC3A5, https://asof.is/claim/clm_3C68D4BBC3A5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000056/0000318154-25-000056-index.htm.","url":"https://asof.is/claim/clm_3C68D4BBC3A5","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"7,428,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3C68D4BBC3A5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2025, filed 2025-08-06"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 87,897,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_A58542830DFC, https://asof.is/claim/clm_A58542830DFC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000056/0000318154-25-000056-index.htm.","url":"https://asof.is/claim/clm_A58542830DFC","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"87,897,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A58542830DFC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2025, filed 2025-08-06"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,432,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_B66FDC24597B, https://asof.is/claim/clm_B66FDC24597B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000056/0000318154-25-000056-index.htm.","url":"https://asof.is/claim/clm_B66FDC24597B","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,432,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B66FDC24597B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2025, filed 2025-08-06"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,656,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_C2025A73F657, https://asof.is/claim/clm_C2025A73F657, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000056/0000318154-25-000056-index.htm.","url":"https://asof.is/claim/clm_C2025A73F657","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,656,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C2025A73F657","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2025, filed 2025-08-06"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 8,028,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_C3AA215549F9, https://asof.is/claim/clm_C3AA215549F9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000056/0000318154-25-000056-index.htm.","url":"https://asof.is/claim/clm_C3AA215549F9","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"8,028,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C3AA215549F9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2025, filed 2025-08-06"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 9,179,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_DF01174105A5, https://asof.is/claim/clm_DF01174105A5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000056/0000318154-25-000056-index.htm.","url":"https://asof.is/claim/clm_DF01174105A5","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"9,179,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DF01174105A5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2025, filed 2025-08-06"}},{"date":"2025-07-31","until":"2025-10-30","published":"2025-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 538,361,851 shares\", as of 2025-07-31 (until 2025-10-30). Claim clm_A337751C1DB4, https://asof.is/claim/clm_A337751C1DB4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000056/0000318154-25-000056-index.htm.","url":"https://asof.is/claim/clm_A337751C1DB4","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"538,361,851 shares","status":"superseded","assertable":true,"id":"clm_A337751C1DB4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2025, filed 2025-08-06"}},{"date":"2025-09-30","until":"2025-12-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 9,619,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_25EEFB9574DF, https://asof.is/claim/clm_25EEFB9574DF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_25EEFB9574DF","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"9,619,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_25EEFB9574DF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-05"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 9,557,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_56EFD8BFD444, https://asof.is/claim/clm_56EFD8BFD444, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_56EFD8BFD444","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"9,557,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_56EFD8BFD444","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-11-05"}},{"date":"2025-09-30","until":"2025-12-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 9,445,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_8E5607E4B59B, https://asof.is/claim/clm_8E5607E4B59B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_8E5607E4B59B","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"9,445,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8E5607E4B59B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-11-05"}},{"date":"2025-09-30","until":"2025-12-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 90,141,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_A3A1C9D984F8, https://asof.is/claim/clm_A3A1C9D984F8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_A3A1C9D984F8","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"90,141,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A3A1C9D984F8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-05"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,526,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_A957F605C563, https://asof.is/claim/clm_A957F605C563, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_A957F605C563","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,526,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A957F605C563","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-05"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 3,216,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_E7FF81925833, https://asof.is/claim/clm_E7FF81925833, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_E7FF81925833","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"3,216,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E7FF81925833","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-05"}},{"date":"2025-10-30","until":"2026-02-10","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 538,480,671 shares\", as of 2025-10-30 (until 2026-02-10). Claim clm_2EA05ED8BE57, https://asof.is/claim/clm_2EA05ED8BE57, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_2EA05ED8BE57","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"538,480,671 shares","status":"superseded","assertable":true,"id":"clm_2EA05ED8BE57","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-05"}},{"date":"2025-12-31","until":null,"published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 36,751,000,000 United States dollar\", as of 2025-12-31. Claim clm_3DD4895A6205, https://asof.is/claim/clm_3DD4895A6205, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm.","url":"https://asof.is/claim/clm_3DD4895A6205","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"36,751,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_3DD4895A6205","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2025, filed 2026-02-13"}},{"date":"2025-12-31","until":null,"published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 7,711,000,000 United States dollar\", as of 2025-12-31. Claim clm_70EECF48CD48, https://asof.is/claim/clm_70EECF48CD48, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm.","url":"https://asof.is/claim/clm_70EECF48CD48","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"7,711,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_70EECF48CD48","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-13"}},{"date":"2025-12-31","until":null,"published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 9,080,000,000 United States dollar\", as of 2025-12-31. Claim clm_92AC0DE5846F, https://asof.is/claim/clm_92AC0DE5846F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm.","url":"https://asof.is/claim/clm_92AC0DE5846F","accessed":"2026-11-08"},"kind":"money","predicate":"operating_income","value":"9,080,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_92AC0DE5846F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-13"}},{"date":"2025-12-31","until":"2026-03-31","published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 90,586,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_D061D89A7312, https://asof.is/claim/clm_D061D89A7312, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm.","url":"https://asof.is/claim/clm_D061D89A7312","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"90,586,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D061D89A7312","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2025, filed 2026-02-13"}},{"date":"2025-12-31","until":"2026-03-31","published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 8,658,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_DEE8552AC913, https://asof.is/claim/clm_DEE8552AC913, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm.","url":"https://asof.is/claim/clm_DEE8552AC913","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"8,658,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DEE8552AC913","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2025, filed 2026-02-13"}},{"date":"2025-12-31","until":"2026-03-31","published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 9,129,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_F9355A194FAC, https://asof.is/claim/clm_F9355A194FAC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm.","url":"https://asof.is/claim/clm_F9355A194FAC","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"9,129,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F9355A194FAC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2025, filed 2026-02-13"}},{"date":"2026-02-10","until":"2026-04-27","published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 539,067,675 shares\", as of 2026-02-10 (until 2026-04-27). Claim clm_231B73F793B2, https://asof.is/claim/clm_231B73F793B2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm.","url":"https://asof.is/claim/clm_231B73F793B2","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"539,067,675 shares","status":"superseded","assertable":true,"id":"clm_231B73F793B2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2025, filed 2026-02-13"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 92,504,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_109E7FAE5B37, https://asof.is/claim/clm_109E7FAE5B37, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000057/0000318154-26-000057-index.htm.","url":"https://asof.is/claim/clm_109E7FAE5B37","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"92,504,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_109E7FAE5B37","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2026, filed 2026-05-01"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 9,190,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_598BA8F87C16, https://asof.is/claim/clm_598BA8F87C16, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000057/0000318154-26-000057-index.htm.","url":"https://asof.is/claim/clm_598BA8F87C16","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"9,190,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_598BA8F87C16","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2026, filed 2026-05-01"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,666,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_8FA61AE28EA3, https://asof.is/claim/clm_8FA61AE28EA3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000057/0000318154-26-000057-index.htm.","url":"https://asof.is/claim/clm_8FA61AE28EA3","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"2,666,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8FA61AE28EA3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2026, filed 2026-05-01"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 12,038,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_93389ECFE0A1, https://asof.is/claim/clm_93389ECFE0A1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000057/0000318154-26-000057-index.htm.","url":"https://asof.is/claim/clm_93389ECFE0A1","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"12,038,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_93389ECFE0A1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2026, filed 2026-05-01"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 1,819,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_B9855476A1FF, https://asof.is/claim/clm_B9855476A1FF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000057/0000318154-26-000057-index.htm.","url":"https://asof.is/claim/clm_B9855476A1FF","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,819,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B9855476A1FF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2026, filed 2026-05-01"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 8,618,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_BA3B03AF2A85, https://asof.is/claim/clm_BA3B03AF2A85, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000057/0000318154-26-000057-index.htm.","url":"https://asof.is/claim/clm_BA3B03AF2A85","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"8,618,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BA3B03AF2A85","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2026, filed 2026-05-01"}},{"date":"2026-04-27","until":"2026-07-30","published":"2026-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 539,708,274 shares\", as of 2026-04-27 (until 2026-07-30). Claim clm_04AAD52EA082, https://asof.is/claim/clm_04AAD52EA082, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000057/0000318154-26-000057-index.htm.","url":"https://asof.is/claim/clm_04AAD52EA082","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"539,708,274 shares","status":"superseded","assertable":true,"id":"clm_04AAD52EA082","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2026, filed 2026-05-01"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 2,375,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_159BCD3BFBBD, https://asof.is/claim/clm_159BCD3BFBBD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/0000318154-26-000126-index.htm.","url":"https://asof.is/claim/clm_159BCD3BFBBD","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"2,375,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_159BCD3BFBBD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2026, filed 2026-08-05"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 95,639,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_716046ECC37B, https://asof.is/claim/clm_716046ECC37B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/0000318154-26-000126-index.htm.","url":"https://asof.is/claim/clm_716046ECC37B","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"95,639,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_716046ECC37B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2026, filed 2026-08-05"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 13,989,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_89D0D620B239, https://asof.is/claim/clm_89D0D620B239, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/0000318154-26-000126-index.htm.","url":"https://asof.is/claim/clm_89D0D620B239","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"13,989,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_89D0D620B239","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2026, filed 2026-08-05"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 11,688,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_D4E836330B03, https://asof.is/claim/clm_D4E836330B03, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/0000318154-26-000126-index.htm.","url":"https://asof.is/claim/clm_D4E836330B03","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"11,688,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D4E836330B03","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2026, filed 2026-08-05"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 3,514,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_DBECC41209EA, https://asof.is/claim/clm_DBECC41209EA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/0000318154-26-000126-index.htm.","url":"https://asof.is/claim/clm_DBECC41209EA","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"3,514,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DBECC41209EA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2026, filed 2026-08-05"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 10,054,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_EE4AA58E7ACE, https://asof.is/claim/clm_EE4AA58E7ACE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/0000318154-26-000126-index.htm.","url":"https://asof.is/claim/clm_EE4AA58E7ACE","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"10,054,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EE4AA58E7ACE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2026, filed 2026-08-05"}},{"date":"2026-07-30","until":"2026-10-29","published":"2026-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 540,632,005 shares\", as of 2026-07-30 (until 2026-10-29). Claim clm_07D435B08217, https://asof.is/claim/clm_07D435B08217, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/0000318154-26-000126-index.htm.","url":"https://asof.is/claim/clm_07D435B08217","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"540,632,005 shares","status":"superseded","assertable":true,"id":"clm_07D435B08217","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2026, filed 2026-08-05"}},{"date":"2026-09-30","until":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 14,352,000,000 United States dollar\", as of 2026-09-30. Claim clm_1845D943407A, https://asof.is/claim/clm_1845D943407A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm.","url":"https://asof.is/claim/clm_1845D943407A","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,352,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_1845D943407A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-11-04"}},{"date":"2026-09-30","until":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 13,190,000,000 United States dollar\", as of 2026-09-30. Claim clm_682A30955369, https://asof.is/claim/clm_682A30955369, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm.","url":"https://asof.is/claim/clm_682A30955369","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"13,190,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_682A30955369","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-11-04"}},{"date":"2026-09-30","until":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 96,048,000,000 United States dollar\", as of 2026-09-30. Claim clm_8D59A495A2F7, https://asof.is/claim/clm_8D59A495A2F7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm.","url":"https://asof.is/claim/clm_8D59A495A2F7","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"96,048,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_8D59A495A2F7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-11-04"}},{"date":"2026-09-30","until":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 3,864,000,000 United States dollar\", as of 2026-09-30. Claim clm_92C83000279C, https://asof.is/claim/clm_92C83000279C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm.","url":"https://asof.is/claim/clm_92C83000279C","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"3,864,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_92C83000279C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-04"}},{"date":"2026-09-30","until":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 10,365,000,000 United States dollar\", as of 2026-09-30. Claim clm_985DF46177C9, https://asof.is/claim/clm_985DF46177C9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm.","url":"https://asof.is/claim/clm_985DF46177C9","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"10,365,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_985DF46177C9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2026, filed 2026-11-04"}},{"date":"2026-09-30","until":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 3,710,000,000 United States dollar\", as of 2026-09-30. Claim clm_B7EB0BB6DBEB, https://asof.is/claim/clm_B7EB0BB6DBEB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm.","url":"https://asof.is/claim/clm_B7EB0BB6DBEB","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_operating_income","value":"3,710,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_B7EB0BB6DBEB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-04"}},{"date":"2026-10-29","until":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 540,911,490 shares\", as of 2026-10-29. Claim clm_E74CF4B58FED, https://asof.is/claim/clm_E74CF4B58FED, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm.","url":"https://asof.is/claim/clm_E74CF4B58FED","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"540,911,490 shares","status":"valid","assertable":true,"id":"clm_E74CF4B58FED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-11-04"}}],"complete":true,"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{"low_confidence":"Confidence below 0.5, the line the record asserts at.","unverified":"Unverified: one source that is not primary, or a primary source below confidence 0.7. Asserted once a primary source or a second independent domain confirms it."},"checked_by":{"sec-filing":"parsed from the SEC filing","own-site":"the entity's own site names it (a website whose page names the entity, a handle its website links to)"}}}